

Pipeline assets and clinical trials appendix Q4 2023



Innovation: Pipeline growth

Clinical trials

Infectious disease

HIV

Respiratory/Immunology

Oncology

Opportunity driven

Innovation: Pipeline growth

Overview of potential new vaccines and medicines

Infectious diseases HIV (ViiV) Respiratory/Immunology Oncology Opportunity driven

4

71 potential new vaccines and medicines in pipeline

Phase III / Registration – 18 assets

Arexvy (RSV vaccine)	Recombinant protein, adjuvanted* RSV older adult	
gepotidacin (2140944)	BTI inhibitor*	Uncomplicated UTI**
bepirovirsen (3228836)	Antisense oligonucleotide*	Chronic HBV infection**
Bexsero (MenB vaccine)	Recombinant protein, OMV	Meningitis B (infants US)
MenABCWY vaccine (3536819)	Recombinant protein, OMV, conjugated vaccine	MenABCWY, 1 st Gen
tebipenem pivoxil (3778712)	Antibacterial carbapenem*	Complicated UTI
ibrexafungerp (5458448)	Antifungal glucan synthase inhibitor*	Invasive candidiasis
Nucala (mepolizumab)	Anti-IL5 antibody	COPD
depemokimab (3511294)	Long-acting anti-IL5 antibody*	Asthma**
latozinemab (4527223)	Anti-sortilin antibody*	Frontotemporal dementia ¹ **
camlipixant (5464714)	P2X3 receptor antagonist	Refractory chronic cough
Low carbon version of MDI ² , <i>Ventolin</i> (salbutamol)	Beta 2 adrenergic receptor agonist	Asthma ³
<i>Ojjaara/Omjjara</i> (momelotinib)	JAK1, JAK2 and ACVR1 inhibitor*	Myelofibrosis^4
<i>Jemperli</i> (dostarlimab)	Anti-PD-1 antibody*	Endometrial cancer^**
Zejula (niraparib)	PARP inhibitor*	Ovarian cancer**
Blenrep (belantamab mafodotin)	Anti-BCMA ADC*	Multiple myeloma
cobolimab (4069889)	Anti-TIM-3 antibody*	Non-small cell lung cancer
linerixibat (2330672)	IBAT inhibitor	Cholestatic pruritus in primary biliary cholangitis

Infectious diseases HIV (ViiV) Respiratory/Immunology Oncology Opportunity driven

71 potential new vaccines and medicines in pipeline

Phase II – 30 assets

3437949	Recombinant protein, adjuvanted*	Malaria fractional dose
4406371	Live, attenuated	MMRV new strain
3536852	GMMA*	
3528869	Viral vector with recombinant protein, adjuvanted*	
4023393	Recombinant protein, OMV, conjugated vaccine	MenABCWY, 2 nd Gen ⁵
4178116	Live, attenuated	Varicella new strain
5101956	MAPS*	Adult pneumococcal disease, 24-valent
5101955	MAPS*	Paediatric pneumococcal disease, 24-valent
4106647	Recombinant protein, adjuvanted*	Human papillomavirus⁵
4348413	GMMA	Gonorrhoea ⁵
4382276	mRNA*	Seasonal flu
4396687	mRNA*	COVID-19
3993129	Adjuvanted recombinant subunit	Cytomegalovirus ⁵
3943104	Recombinant protein, adjuvanted*	Therapeutic herpes simplex virus ⁵
5637608	Hepatitis B virus-targeted siRNA*	Chronic HBV infection
4077164	Bivalent GMMA	Invasive non-typhoidal salmonella**
3036656	Leucyl t-RNA synthetase inhibitor*	Tuberculosis
sanfetrinem cilexetil (GV118819)	Serine beta lactamase inhibitor*	Tuberculosis
BVL-GSK098	Ethionamide booster*	Tuberculosis
3810109	Broadly neutralizing antibody*	HIV
3739937	Maturation inhibitor	HIV
4004280	Capsid protein inhibitor	HIV
4011499	Capsid protein inhibitor	HIV
4524184	Integrase inhibitor*	HIV ⁶
Benlysta (belimumab)	Anti-BLys antibody	Systemic sclerosis associated interstitial lung disease
3858279	Anti-CCL17 antibody*	Osteoarthritis pain**
1070806	Anti-IL18 antibody	Atopic dermatitis
4527226 (AL-101)	Anti-sortilin antibody*	Alzheimer's disease ⁶
belrestotug (4428859)	Anti-TIGIT antibody*	Non-small cell lung cancer**
4532990	HSD17B13 siRNA*	Non-alcoholic steatohepatitis

GSK

*In-licence or other alliance relationship with third party ** Additional indications or candidates also under investigation ^ In registration

1. Phase III trial in patients with progranulin gene mutation 2. Metered dose inhaler 3. Phase III start expected in 2024 4. Approved in US and EU 5. In phase I/II study 6. Phase II study start imminent 7. Transition activities underway to enable further progression by partner 8. GSK has an exclusive global license option to co-develop and commercialise the candidate

Infectious diseases HIV (ViiV) Respiratory/Immunology Oncology Opportunity driven

6

71 potential new vaccines and medicines in pipeline

Phase I – 23 assets

3536867	Bivalent conjugate*	Salmonella (typhoid + paratyphoid A)
2556286	Mtb cholesterol dependent inhibitor*	Tuberculosis
3186899	CRK-12 inhibitor* ⁷	Visceral leishmaniasis
3494245	Proteasome inhibitor*	Visceral leishmaniasis
3772701	P. falciparum whole cell inhibitor*	Malaria
4024484	P. falciparum whole cell inhibitor*	Malaria
3882347	FimH antagonist*	Uncomplicated UTI
3923868	PI4K beta inhibitor	Viral COPD exacerbations
3965193	PAPD5/PAPD7 inhibitor	Chronic HBV infection ⁵
5251738	TLR8 agonist*	Chronic HBV infection
cabotegravir (1265744)	Integrase inhibitor	HIV
3888130	Anti-IL7 antibody*	Autoimmune disease
3915393	TG2 inhibitor*	Pulmonary fibrosis
3862995	Anti-IL33 antibody	COPD
5462688	RNA-editing oligonucleotide*	Alpha-1 antitrypsin deficiency
4347859	Interferon pathway modulator	Systemic lupus erythematosus
4381562	Anti-PVRIG antibody*	Cancer
6097608	Anti-CD96 antibody*	Cancer
XMT-2056 ⁹ (wholly owned by Mersana Theraprutics)	STING agonist ADC*	Cancer
belantamab (2857914)	Anti-BCMA antibody	Multiple myeloma
4524101	DNA polymerase theta inhibitor*	Cancer ⁵
5733584 (HS-20089)	ADC-targeting B7-H4*	Gynecologic malignancies
4172239	DNMT1 inhibitor*	Sickle cell disease

Infectious diseases pipeline

Phase III / Registration – 7 assets

Arexvy (RSV vaccine)	Recombinant protein, adjuvanted*
gepotidacin (2140944)	BTI inhibitor*
bepirovirsen (3228836)	Antisense oligonucleotide*
Bexsero (MenB vaccine)	Recombinant protein, OMV
MenABCWY vaccine (3536819)	Recombinant protein, OMV, conjugated vaccine
tebipenem pivoxil (3778712)	Antibacterial carbapenem*
ibrexafungerp (5458448)	Antifungal glucan synthase inhibitor*

RSV older adults (50-59 YoA)^ Uncomplicated UTI** Chronic HBV infection** Meningitis B (infants US) MenABCWY, 1st Gen Complicated UTI Invasive candidiasis

3536867	Bivalent conjugate*
2556286	Mtb cholesterol dependent inhibitor*
3186899	CRK-12 inhibitor* ⁷
3494245	Proteasome inhibitor*
3772701	P. falciparum whole cell inhibitor*
4024484	P. falciparum whole cell inhibitor*
3882347	FimH antagonist*
3923868	PI4K beta inhibitor
3965193	PAPD5/PAPD7 inhibitor
5251738	TLR8 agonist*

Phase I – 10 assets

Salmonella (typhoid + paratyphoid A) Tuberculosis Visceral leishmaniasis Visceral leishmaniasis Malaria Malaria Uncomplicated UTI Viral COPD exacerbations Chronic HBV infection⁵

Infectious diseases HIV (ViiV)

Oncology Opportunity driven

Respiratory/Immunology

Chronic HBV infection

Phase II – 19 assets

3437949	Recombinant protein, adjuvanted*	Malaria fractional dose
4406371	Live, attenuated	MMRV new strain
3536852	GMMA*	Shigella
3528869	Viral vector with recombinant protein, adjuvanted*	Chronic HBV infection ⁵ **
4023393	Recombinant protein, OMV, conjugated vaccine	MenABCWY, 2 nd Gen ⁵
4178116	Live, attenuated	Varicella new strain
5101956	MAPS*	Adult pneumococcal disease, 24-valent
5101955	MAPS*	Paediatric pneumococcal disease, 24-valent
4106647	Recombinant protein, adjuvanted*	Human papillomavirus⁵
4348413	GMMA	Gonorrhoea ⁵
4382276	mRNA*	Seasonal flu
4396687	mRNA*	COVID-19
3993129	Adjuvanted recombinant subunit	Cytomegalovirus ⁵
3943104	Recombinant protein, adjuvanted*	Therapeutic herpes simplex virus ⁵
5637608	Hepatitis B virus-targeted siRNA*	Chronic HBV infection
4077164	Bivalent GMMA	Invasive non-typhoidal salmonella**
3036656	Leucyl t-RNA synthetase inhibitor*	Tuberculosis
sanfetrinem cilexetil (GV118819)	Serine beta lactamase inhibitor*	Tuberculosis
BVL-GSK098	Ethionamide booster*	Tuberculosis

*In-licence or other alliance relationship with third party **Additional indications or candidates also under investigation ^ In registration 1. Phase III trial in patients with programulin gene mutation 2. Metered dose inhaler 3. Phase III start expected in 2024 4. Approved in US and EU 5. In phase I/I study 6. Phase II study start imminent 7. Transition activities underway to enable further progression by partner 8. Phase I study start imminent 9. GSK has an exclusive global license option to co-develop and commercialise the candidate

HIV pipeline

Phase II – 5 assets


3810109	Broadly neutralizing antibody*	HIV
3739937	Maturation inhibitor	HIV
4004280	Capsid protein inhibitor	HIV
4011499	Capsid protein inhibitor	HIV
4524184	Integrase inhibitor*	HIV ⁶

Phase I – 1 asset

cabotegravir (1265744)	Integrase inhibitor	HIV

Infectious diseases HIV (ViiV) Respiratory/Immunology Oncology Opportunity driven

8



Respiratory/Immunology pipeline

Phase III / Registration – 5 assets

Nucala (mepolizumab)	Anti-IL5 antibody	COPD
depemokimab (3511294)	Long-acting anti-IL5 antibody*	Asthma**
latozinemab (4527223)	Anti-sortilin antibody*	Frontotemporal dementia ¹ **
camlipixant (5464714)	P2X3 receptor antagonist	Refractory chronic cough
Low carbon version of MDI ² , <i>Ventolin</i> (salbutamol)	Beta 2 adrenergic receptor agonist	Asthma ³

Phase II – 4 assets

Benlysta (belimumab)	Anti-BLys antibody	Systemic sclerosis associated interstitial lung disease
3858279	Anti-CCL17 antibody*	Osteoarthritis pain**
1070806	Anti-IL18 antibody	Atopic dermatitis
4527226 (AL-101)	Anti-sortilin antibody*	Alzheimer's disease ⁶

Phase I – 5 assets

3888130	Anti-IL7 antibody*	Autoimmune disease
3915393	TG2 inhibitor*	Pulmonary fibrosis
3862995	Anti-IL33 antibody	COPD
5462688	RNA-editing oligonucleotide*	Alpha-1 antitrypsin deficiency
4347859	Interferon pathway modulator	Systemic lupus erythematosus

Oncology pipeline

Phase III / Registration – 5 assets

<i>Ojjaara/Omjjara</i> (momelotinib)	JAK1, JAK2 and ACVR1 inhibitor*	Myelofibrosis^4
Jemperli (dostarlimab)	Anti-PD-1 antibody*	Endometrial cancer^**
Zejula (niraparib)	PARP inhibitor*	Ovarian cancer**
Blenrep (belantamab mafodotin)	Anti-BCMA ADC*	Multiple myeloma
cobolimab (4069889)	Anti-TIM-3 antibody*	Non-small cell lung cancer


Phase II – 1 asset

belr	estotug (4428859)	Anti-TIGIT antibody*	Non-small cell lung cancer**

Phase I – 6 assets

4381562	Anti-PVRIG antibody*	Cancer
6097608	Anti-CD96 antibody*	Cancer
XMT-2056 ⁸ (wholly owned by Mersana Theraprutics)	STING agonist ADC*	Cancer
belantamab (2857914)	Anti-BCMA antibody	Multiple myeloma
4524101	DNA polymerase theta inhibitor*	Cancer ⁵
5733584 (HS-20089)	ADC-targeting B7-H4*	Gynecologic malignancies

10



11

Opportunity driven pipeline Phase III / Registration – 1 asset

linerixibat (2330672)	IBAT inhibitor	Cholestatic pruritus in primary biliary cholangitis
Phase II – 1 asset		
4532990	HSD17B13 siRNA*	Non-alcoholic steatohepatitis
Phase I – 1 asset		
4172239	DNMTI inhibitor*	Sickle cell disease

In -licence or other alliance relationship with third party ** Additional indications or candidates also under investigation ^ In registration
In -licence or other alliance relationship with third party ** Additional indications or candidates also under investigation ^ In registration
I. Phase III trial in patients with progranulin gene mutation 2. Metered dose inhaler 3. Phase III start expected in 2024 4. Approved in US and EU 5. In phase I/II study 6. Phase II study start imminent 7. Transition activities underway to enable further progression by partner 8. GSK has an exclusive global license option to co-develop and commercialise the candidate

Changes since Q3 2023

Changes on pipeline

New to Phase I

4024484 – *P. falciparum* whole cell inhibitor, malaria 3862995 – Anti-IL33 antibody, COPD 5462688 – RNA-editing oligonucleotide, Alpha-1 antitrypsin deficiency 4347859 – Interferon pathway modulator, systemic lupus erythematosus 5733584 – ADC targeting B7-H4, gynecologic malignancies

New to Phase II

3943104 – Recombinant protein, adjuvanted, Therapeutic HSV 5637608 – HBV-targeted siRNA sequential combination, chronic HBV infection 4077164 – Bivalent GMMA, Invasive non-typhoidal salmonella** 4524184 – Integrase inhibitor, HIV

New to Phase III

Low carbon version of MDI, Ventolin – Beta 2 adrenergic receptor agonist, asthma

Removed from Phase I



4429016 – Bioconjugated recombinant protein, adjuvanted, *K. pneumoniae* 4182137 (VIR7832) – Anti-spike protein antibody, COVID-19

Removed from Phase II

VIR2482 – Neutralising monoclonal antibody, influenza


Infectious diseases HIV (ViiV) Respiratory/Immunology Oncology Opportunity driven

Achieved pipeline catalysts

Regulatory decisions

<i>Nucala</i> – severe asthma	CN
Jemperli ¹ – RUBY, dMMR/MSI-H 1L endometrial cancer	EU
Omjjara: MOMENTUM, myelofibrosis	EU

Regulatory submission acceptances



EU, JP

Other events



Blenrep – DREAMM-7, 2L+ MM – Positive headline phase III data Jemperli¹ – RUBY (Part 2), 1L EC – Positive phase III data readout

Upcoming pipeline catalysts: 2024 and 2025

Infectious diseases HIV (ViiV) Respiratory/Immunology Oncology Opportunity driven

	H1 2024		H2 2024		2025	
Regulatory	Ojjaara/Omjjara: MOMENTUM, myelofibrosis	JP	Arexvy: 50-59 YoA ¹⁰	US, EU, JP	gepotidacin: EAGLE-2/3, uUTI ¹¹	US
decision	_		Nucala: CRSwNP ¹	JP	gepotidacin: EAGLE-1, GC ⁵	US
					MenABCWY vaccine 1st Gen	US, EU
					depemokimab: SWIFT-1/2, asthma	US
					depemokimab: ANCHOR-1/2, CRSwNP ¹	US
					Nucala: CRSwNP ¹	CN
					Nucala: MATINEE, COPD ¹²	US
					Blenrep: DREAMM-7/8, 2L+ MM ⁷	US, EU, CN, JP
					Jemperli ² : RUBY (Part 1) ^{3,} 1L EC ⁴	US
					linerixibat: GLISTEN, cholestatic pruritus in PBC ¹⁴	US
Regulatory	MenABCWY vaccine 1st Gen	US	gepotidacin: EAGLE-2/3, uUTI ¹¹	US	gepotidacin: EAGLE-1, GC⁵	US
submission and	Nucala: CRSwNP ¹	CN	MenABCWY vaccine 1st Gen	EU	tebipenem pivoxil: PIVOT-PO, cUTI ¹⁵	US
acceptance	Jemperli ² : RUBY (Part 1) ³ , 1L EC ⁴	US	depemokimab: SWIFT-1/2, asthma	US	camlipixant: CALM-1/2, RCC ¹⁶	US, EU
			depemokimab: ANCHOR-1/2, CRSwNP ¹	US	Nucala: MATINEE, COPD ¹²	EU, CN
			Nucala: MATINEE, COPD ¹²	US	Blenrep: DREAMM-7/8, 2L+ MM ⁷	US, EU, CN, JP
			_		cobolimab ² : COSTAR, 2L NSCLC ¹³	US, EU
					linerixibat: GLISTEN, cholestatic pruritus in PBC ¹⁴	US, EU, CN, JP
Late-stage phase	gepotidacin: EAGLE-1, GC⁵		depemokimab: ANCHOR-1/2, CRSwNP ¹		tebipenem pivoxil: PIVOT-PO, cUTI ¹⁵	
III and phase II	depemokimab: SWIFT-1/2, asthma		Nucala: MATINEE, COPD ¹²		camlipixant: CALM-1/2, RCC ¹⁶	
readouts	Blenrep: DREAMM-7 ⁶ , 2L+ MM ⁷		Blenrep: DREAMM-8, 2L+ MM ⁷ depemokimab: OCEAN, EGPA ¹⁷		depemokimab: OCEAN, EGPA ¹⁷	
	Zejula ² : FIRST, 1L maintenance OC ⁸		cobolimab ² : COSTAR, 2L NSCLC ¹³		—	
	—		Zejula ² : ZEAL, 1L maintenance NSCLC ¹³			
	mRNA Seasonal flu ⁹		linerixibat: GLISTEN, cholestatic pruritus in PBC	714		

ĿSK

1. Chronic rhinosinusitis with nasal polyps 2. Tesaro asset 3. Overall population 4. Endometrial cancer 5. Urogenital gonorrhoea 6. Overall survival 7. Multiple myeloma 8. Ovarian cancer 9. Phase II 10. Years of age 11. 13 Uncomplicated urinary tract infection 12. Chronic obstructive pulmonary disorder 13. Non-small cell lung cancer 14. Treatment of cholestatic pruritus in primary biliary cholangitis 15. Complicated urinary tract infection 16. Refractory chronic cough 17. Eosinophilic granulomatosis with polyangiitis

Designations in our pipeline

101956	MAPS*	Adult pneumococcal disease, 24-valent
ast Track		
382276	mRNA*	Seasonal flu
3VL-GSK098	Ethionamide booster*	Tuberculosis
1348413	GMMA	Gonorrhoea
gepotidacin (2140944)	BTI inhibitor*	Urogenital gonorrhoea
ebipenem pivoxil (3778712)	Antibacterial carbapenem*	Complicated UTI
3858279	Anti-CCL17 antibody*	Osteoarthritis pain
3858279	Anti-CCL17 antibody*	Diabetic peripheral neuropathic pain
	Anti-sortilin antibody*	Frontotemporal dementia ²
<i>lemperli¹</i> (dostarlimab)	Anti-PD-1 antibody*	Neoadjuvant dMMR/MSI-H1L rectal cancer
1172239	DNMT1 inhibitor*	Sickle cell disease

Orphan Drug Designation

ibrexafungerp (5458448) US	Antifungal glucan synthase inhibitor*	Invasive candidiasis
Benlysta (belimumab) US	Anti-BLys antibody	Systemic sclerosis associated interstitial lung disease
latozinemab (4527223) US, EU	Anti-sortilin antibody*	Frontotemporal dementia ²
depemokimab (3511294) JP	Long-acting anti-IL5 antibody*	Hypereosinophilic syndrome
linerixibat (2330672) US, EU	IBAT inhibitor	Cholestatic pruritus in primary biliary cholangitis

Qualified Infectious Disease Product Designation

gepotidacin (2140944)	BTI inhib
tebipenem pivoxil (3778712)	Antibact

itor* terial carbapenem* BREAKTHROUGH DESIGNATION (US) - a process designed to expedite the development and review of medicines intended to treat serious conditions, where preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available therapy

Infectious diseases HIV (ViiV)

Oncology Opportunity driven

Respiratory/Immunology

FAST TRACK (US) - a program designed to facilitate the expedited development and review of medicines to treat serious conditions and fill an unmet medical need

OPHAN DRUG DESIGNATION - intended for treatment, diagnosis or prevention of rare disease/disorders that affect fewer than 200,000 patients in the US, or not more than 5 in 10,000 in the EU or that affect more than this number of patients but are not expected to recover the costs of developing and marketing a treatment drug, or if intended for use in less than 50,000 patients in Japan and for which there is a high medical need

QUALIFIED INFECTIOUS DISEASE PRODUCT DESIGNATION (US) - an antibacterial or antifungal drug for human use intended to treat serious or lifethreatening infections

5

Uncomplicated UTI and urogenital gonorrhoea Complicated UTI

Innovation: Pipeline growth	
-----------------------------	--

Glossary

Clinical Trials

Glossary

Opportunity driven

Infectious diseases Arexvy (RSV Older Adults)

Infectious diseases

NCT04732871 - RSV OA=ADJ-004

Phase	III	F
Patient	Adults ≥60 years of age	ŀ
Subjects	1653	
	Arm A: RSVPreF3 OA Day 1, 12 months & 24 months	
Treatment arms	Arm B: RSVPreF3 OA Day 1 and 24 months	
anns	Arm C: RSVPreF3 OA Day 1 then follow up	7 c
Description	A randomised, open-label, multi-country trial to evaluate the immunogenicity, safety, reactogenicity and persistence of a single dose of the RSVPreF3 OA investigational vaccine and different revaccination schedules in adults aged 60 years and above	_
 . ,.	Trial start: Q1 2021	Ľ
Timeline	Primary data reported: Q2 2022	_
Key end points	Humoral immune response following a 1 dose primary schedule up to 12 months post dose 1	۲
Clinicaltrials.g ov	Link	۱ ۴
		(

NCT04886596 - RSV OA=ADJ-006

Phase	III		
Patient	Adults ≥60 years of age		
Subjects	24,966		
	Arm A: RSVPreF3 OA Lot 1		
	Arm B: RSVPreF3 OA Lot 2		
Treatment arms	Arm C: RSVPreF3 OA Lot 3		
Ginis	Arm D: RSVPreF3 OA Lot 4		
	Arm E: Placebo		
Description	A randomised, placebo-controlled, observer-blind, multi-country trial to demonstrate the efficacy of a single dose and annual revaccination doses of GSK's RSVPreF3 OA investigational vaccine in adults aged 60 years and above		
	Trial start: Q2 2021		
Timeline	Primary data reported: Q2 2022; season two data reported Q2 2023		
Key end points	Efficacy of a single dose and annual revaccination doses of RSVPreF3 OA vaccine in the prevention of RSV-LRTD in adults ≥ 60 yoa		
Clinicaltrials.g ov	Link		

Infectious diseases Arexvy (RSV Older Adults)

Infectious diseases

NCT04841577	- RSV	OA=AD.	J-007
-------------	-------	--------	-------

Phase	ш
Patient	Adults ≥60 years of age
Subjects	885
Treatment arms	Arm A: 1 dose of RSVPreF3 OA + 1 dose of FLU-QIV on Day 1
	Arm B: 1 dose of FLU-QIV on Day 1, 1 dose of RSVPreF3 OA on Day 31
Description	An open-label, randomised, controlled, multi-country trial to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with FLU-QIV vaccine in adults aged 60 years and above
Timeline	Trial start: Q2 2021
	Primary data reported: Q4 2022
Key end points	Humoral immune response 1 month post vaccination upon co-administration compared to the immune response when vaccine is administered alone
Clinicaltrials.g ov	Link

NCT05559476 - RSV OA=ADJ-008

Phase	III
Patient	Adults aged 65 years and above
Subjects	1028
Treatment	Arm A: 1 dose of RSVPreF3 OA + 1 dose of Flu-HD on day 1
arms	Arm B: 1 dose of Flu HD on Day 1 ,1 dose of RSVPreF3 OA on Day 31
Description	An open-label, randomised, controlled, multi-country trial to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with FLU HD vaccine in adults aged 65 years and above
Timeline	Trial start: Q4 2022
IImeline	Primary data reported: Q2 2023
Key end points	Humoral immune response 1 month post vaccination upon co-administration compared to the immune response when vaccine is administered alone
Clinicaltrials.g ov	Link

Opportunity driven

Glossary

Opportunity driven

Infectious diseases Arexvy (RSV Older Adults)

Infectious diseases

NCT05059301 -	RSV OA=ADJ-009
---------------	----------------

Phase	ш
Patient	Adults aged 60 years and above
Subjects	770
Treatment arms	Arm A: 1 dose of a combination of the RSVPreF3 antigen Lot 1 and AS01E adjuvant Lot A at day 1
	Arm B: 1 dose of a combination of the RSVPreF3 antigen Lot 2 and AS01E adjuvant Lot B at day 1
	Arm C: 1 dose of a combination of the RSVPreF3 antigen Lot 3 and AS01E adjuvant Lot C at Day 1
Description	A randomised, double-blind, multi-country trial to evaluate consistency, safety and reactogenicity of 3 lots of RSVPreF3 OA investigational vaccine administrated as a single dose in adults aged 60 years and above
Timeline	Trial start: Q4 2021
limeline	Trial end: Q2 2022
Key end points	RSVPreF3-binding IgG concentrations at 1 month post vaccination for three lots of RSVPreF3 OA investigational vaccine
Clinicaltrials.g ov	Link

NCT05568797 - RSV OA=ADJ-017

Phase	III
Patient	Adults aged 65 years and above
Subjects	880
Treatment	Arm A: 1 dose RSVPreF3 OA investigational vaccine and 1 dose of FLU aQIV vaccine on Day 1
arms	Arm B: one dose of Flu aQIV on day 1 and 1 dose of RSVPreF3 OA on day 31
Description	An open-label, randomised, controlled, multi-country trial to evaluate the immune response, safety and reactogenicity of an RSVPreF3 OA investigational vaccine when co-administered with FLU aQIV (inactivated influenza vaccine – adjuvanted) in adults aged 65 years and above
T '	Trial start: Q4 2022
Timeline	Primary data reported: Q2 2023
Key end points	Humoral immune response 1 month post vaccination upon co-administration compared to the immune response when vaccine is administered alone
Clinicaltrials.g ov	Link

Infectious diseases Arexvy (RSV Older Adults)

Infectious diseases

NCT05590403 - RSV OA-018

Phase	III
Patient	Adults 50-59 years of age, including adults at increased risk of respiratory syncytial virus lower respiratory tract disease, and older adults ≥60 years of age
Subjects	1520
	Arm A: adults HA-RSVPreF3 OA Group
	Arm B: adults HA-Placebo Group
Treatment arms	Arm C: adults AIR-RSVPReF3 OA Group
anno	Arm D: adults AIR-Placebo Group
	Arm E: OA-RSVPReF3 OA Group ≥60 years of age
Description	An observer-blind, randomised, placebo-controlled trial to evaluate the non- inferiority of the immune response and safety of the RSVPreF3 OA investigational vaccine in adults 50 59 years of age, including adults at increased risk of respiratory syncytial virus lower respiratory tract disease, compared to older adults ≥60 years of age
	Trial start: Q4 2022
Timeline	Primary data reported: Q4 2023
Key end points	Humoral immune response in healthy participants 50-59 years of age and in participants 50-59 years of age at increased risk of RSV-LRTD compared to OA (≥ 60 yoa)
Clinicaltrials.g ov	Link

NCT05879107 - RSV OA=ADJ-019

Phase	III
Patient	Adults ≥60 years of age
Subjects	1090
Treatment arms	Arm A (co-ad group): RSVPreF3 OA investigational vaccine co-administered with PCV20 vaccine
	Arm B (control group): PCV20 vaccine on Day 1 and the RSVPreF3 OA investigational vaccine on Day 31.
Description	An open-label, randomised, controlled, multi-country study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with PCV20 in adults aged 60 years and older
T ime of C ine of	Trial start: Q2 2023
Timeline	Data anticipated: H2 2024
Key end points	Opsonophagocytic antibody titers for each of the pneumococcal vaccine serotypes and RSV-A & RSV-B serum neutralizing titers
Clinicaltrials.g ov	Link

Infectious diseases Arexvy (RSV Older Adults)

Infectious diseases

NCT05966090 - RSV OA=ADJ-020

Phase	III
Patient	Adults aged 50 years and older
Subjects	530
Treatment arms	Arm A: Participants will be administered first dose of HZ/su vaccine and the RSVPreF3 OA investigational vaccine together on Day 1. A second dose of the HZ/su vaccine will be administered at Day 61.
	Arm B: Participants will be administered first dose HZ/su vaccine on Day 1, followed by the RSVPreF3 OA investigational vaccine on Day 31, and then second dose of HZ/su vaccine on Day 61.
Description	An open-label, randomised, controlled, multi-country study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with Herpes Zoster recombinant subunit (HZ/su) vaccine in adults aged 50 years and older
	Trial start: Q3 2023
Timeline	Data anticipated: H2 2024
Key end points	Anti-gE antibody concentrations expressed as group geometric mean concentration ratio
	RSV-A & -B serum neutralizing titers expressed as group geometric mean titer
Clinicaltrials.g ov	Link
GSK	

NCT05921903 - RSV OA=ADJ-023

Phase	Пр
Patient	Immunocompromised (IC) adults 50 years of age and above
Subjects	375
Treatment arms	Arm A: RSV_IC_1 group, IC patients receiving 1 dose of RSVPreF3 OA investigational vaccine at Visit 1 (Day 1).
	Arm B: RSV_IC_2 group, IC patients receiving 2 doses of RSVPreF3 OA investigational vaccine at Visit 1 (Day 1) and Visit 3 (Visit 1 + 30-60 days)
	Arm C: RSV_HA group, healthy participants receiving 1 dose of RSVPreF3 OA investigational vaccine at Visit 1 (Day 1).
Description	A randomised, controlled, open-label trial to evaluate the immune response and safety of the RSVPreF3 OA investigational vaccine in adults (≥50 years of age) when administered to lung and renal transplant recipients comparing one versus two doses and compared to healthy controls (≥50 years of age) receiving one dose
Timeline	Trial start: Q3 2023
i imeline	Data anticipated: 2025
Key end points	RSV-A & -B serum neutralizing titers expressed as mean geometric increase post Dose 2 over post Dose 1
Clinicaltrials.g ov	Link

21

Infectious diseases

Infectious diseases gepotidacin

NCT04010539 - EAGLE 1

Phase	III
Patient	Uncomplicated urogenital gonorrhoea caused by Neisseria gonorrhoeae
Subjects	1531
Treatment	Arm A: 2 x 3000 mg gepotidacin for one day
arms	Arm B: ceftriaxone (500mg IM), 1 g azithromycin
Description	A randomised, multicentre, open-label trial in adolescent and adult participants comparing the efficacy and safety of gepotidacin to ceftriaxone plus azithromycin in the treatment of uncomplicated urogenital gonorrhoea caused by <i>Neisseria gonorrhoeae</i>
Timeline	Trial start: Q4 2019
	Data anticipated: H1 2024
Key end points	Number of participants with culture-confirmed bacterial eradication 4-8 days post treatment
Clinicaltrials.g ov	Link

NCT04020341 - EAGLE 2

Phase	III
Patient	Females with uUTI / acute cystitis
Subjects	1531
Treatment	Arm A: 1500 mg BID gepotidiacin + placebo x 5 days
arms	Arm B: 100 mg BID nitrofurantoin + placebo x 5 days
Description	A randomised, multicentre, parallel-group, double-blind, double-dummy trial in adolescent and adult female participants comparing the efficacy and safety of gepotidacin to nitrofurantoin in the treatment of uncomplicated urinary tract infection (acute cystitis)
Timeline	Trial start: Q4 2019
Ilmeline	Data reported: Q2 2023
Key end points	Number of participants with therapeutic response (combined per participant clinical and microbiological response)
Clinicaltrials.g ov	Link

Opportunity driven

HIV

Glossary

Infectious diseases gepotidacin

NCT04187144 - EAGLE 3

Phase	III
Patient	Females with uUTI / acute cystitis
Subjects	1606
Treatment arms	Arm A: 1500 mg BID gepotidiacin + placebo x 5 days
	Arm B: 100 mg BID nitrofurantoin + placebo x 5 days
Description	A randomised, multicentre, parallel-group, double-blind, double-dummy trial in adolescent and adult female participants comparing the efficacy and safety of gepotidacin to nitrofurantoin in the treatment of uncomplicated urinary tract infection (acute cystitis)
Timeline	Trial start: Q2 2020
	Data reported: Q2 2023
Key end points	Number of participants with therapeutic response (combined per participant clinical and microbiological response)
Clinicaltrials.g ov	Link

Infectious diseases

Infectious diseases

bepirovirsen

NCT05630807 - B-WELL 1

Phase	III	
Patient	Non-cirrhotic nucleos(t)ide analogue treated patients with chronic hepatitis B virus	
Subjects	900	
Treatment	Arm A: bepirovirsen for 24 weeks	
arms	Arm B: placebo	
Description	Phase III multicentre, randomised, double blind trial to confirm the efficacy and safety of treatment with bepirovirsen in participants with chronic hepatitis B virus	
T :	Trial start: Q1 2023	
Timeline	Data anticipated: 2026+	
Key end points	Number of participants achieving functional cure (FC) with baseline HBsAg≤ 3000IU/mL	
Clinicaltrials.g ov	Link	

NCT05630820 - B-WELL 2

Phase	III	
Patient	Non-cirrhotic nucleos(t)ide analogue treated patients with chronic hepatitis B virus	
Subjects	900	
Treatment	Arm A: bepirovirsen for 24 weeks	
arms	Arm B: placebo	
Description	Phase III multicentre, randomised, double blind trial to confirm the efficacy and safety of treatment with bepirovirsen in participants with chronic hepatitis B virus	
Timeline	Trial start: Q1 2023	
Imeline	Data anticipated: 2026+	
Key end points	Number of participants achieving functional cure (FC) with baseline HBsAg≤ 3000IU/mL	
Clinicaltrials.g ov	Link	

HIV

Glossary

Infectious diseases

bepirovirsen

NCT04676724 - B-TOGETHER

Phase	llb	
Patient	ient Non-cirrhotic patients with chronic hepatitis B virus on stable nucleos(t)ide analog therapy	
Subjects	108	
Treatment	Arm A: bepirovirsen for 12 wks + PegIFN for =< 24 wks	
arms	Arm B: bepirovirsen for 24 weeks + PegIFN =< 24 wks	
Description	A multicentre, randomised, open label trial to assess the efficacy and safety of sequential treatment with bepirovirsen followed by Pegylated Interferon Alpha 2a in participants with chronic hepatitis B virus	
Timeline	Trial start: Q1 2021	
Ilmeline	Data reported: Q4 2023	
Key end points	Sustained response for 24 weeks post treatment	
Clinicaltrials.g ov	Link	

NCT05276297

Phase	П	
Patient	HBV suppressed subjects under nucleo(s)tide treatment	
Subjects	184	
	ASO24-targeted immunotherapy group (GSK3228836 (24-week treatment) followed by GSK3528869A)	
Treatment	ASO24 group (GSK3228836 (24-week treatment) followed by non-active control)	
arms	ASO12-targeted immunotherapy group (GSK3228836 (12-week treatment) followed by GSK3528869A)	
	ASO12 group (GSK3228836 (12-week treatment) followed by non-active control)	
A single-blinded, randomised, controlled multi-country trial to evaluate safety, reactogenicity, efficacy and immune response following sector treatment with an anti-sense oligonucleotide against Chronic Heper (CHB) followed by Chronic Hepatitis B Targeted Immunotherapy (CHB patients receiving nucleos(t)ide analogue (NA) therapy		
Timeline	Trial start: Q2 2022 Data anticipated: 2025	
Key end pointsNumber of subjects reporting local and general AEs and percentage of participants with sustained virologic response		
Clinicaltrials.g ov	Link	

-25

HIV

Glossary

Infectious diseases MenABCWY

NCT04707391 - MenABCWY-019

Phase	IIIb	
Patient	Healthy adolescents and adults aged 15-25 years	
Subjects	1250	
Treatment	Arm A: 2 doses of MenABCWY days 1, 181 + placebo day 211	
arms	Arm B: 1 dose MenABCWY day 1; 2 doses of MenB on Day 181 and Day 211	
Description	A randomised, controlled, observer-blind trial to evaluate safety and immunogenicity of GSK's meningococcal ABCWY vaccine when administered in healthy adolescents and adults previously primed with meningococcal ACWY vaccine	
Timeline	Trial start: Q1 2021	
Timeline	Data reported: Q4 2023	
Key end points	hSBA titers	
Clinicaltrials.g ov	Link	

NCT04502693 - MenABCWY V72 72

Phase	111		
Patient	Healthy adolescents and adults ages 10-25 years		
Subjects	3657		
	Arm A: rMenB+OMV NZ (2/3 dose schedule) plus MenACWY		
	Arm B: rMenB+OMV NZ (2 dose schedule) plus MenACWY plus placebo		
Treatment	Arm C: placebo + MenABCWY lot 1		
arms	Arm D: placebo + MenABCWY lot 2		
	Arm E: placebo + MenABCWY lot 3		
	Arm F: rMenB+OMV NZ + MenACWY + placebo		
Description Effectiveness of GSK Biologicals S.A.'s Meningococcal Group B and ABCWY vaccines in healthy adolescents and young adults			
Timeline	Trial start: Q3 2020		
IImeline	Data reported: Q1 2023		
Key end points	hSBA titers		
Clinicaltrials.g ov	Link		

HIV

Opportunity driven

Infectious diseases MenABCWY

NCT05087056 - MenABCWY-020

Phase	llb	
Patient	Healthy adolescents ≥11 to <15 years of age	
Subjects	300	
Treatment	Arm A: ABCWY-24 Group	
arms	Arm B: ABCWY-48 Group	
Description	A randomised, observer-blind trial to describe the safety, tolerability and immunogenicity of MenABCWY administered on different dosing schedules in healthy adolescents	
T!	Trial start: Q4 2021	
Timeline	Data anticipated: 2026+	
Key end points	hSBA titers ≥ LLOQ of each <i>N. meningitidis</i> serogroup B indicator strain	
Clinicaltrials.g ov	Link	

Glossary

Infectious diseases GSK 3437949 (Malaria fractional dose)

Infectious diseases

Phase	llb
Patient	Children aged 5-17 months
Subjects	1498
	R012-20 Group: a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 and Month 20
	R012-14-mD Group: a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 Month 14, Month 26, Month 38
Treatment	Fx012-14-mFxD Group: a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 2, Month 14, Month 26, Month 38
arms	Fx017-mFxD Group: a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 7, Month 20, Month 32
	Control Group: Subjects will receive rabies vaccine at Month 0, Month 1, Month 2
Description	A randomized, open-label, controlled, multi-centre trial of the efficacy, safety and immunogenicity of GSK Biologicals' candidate malaria vaccine RTS,S/AS01E evaluating schedules with or without fractional doses, early Dose 4 and yearly doses, in children 5-17 months of age living in sub-Saharan Africa.
Timeline	Trial start: Q3 2017
	Data anticipated: H2 2023
Key end points	Incremental efficacy of a schedule with a fractional third dose at Month 2 over the standard schedule. To demonstrate the superiority of a 3- dose schedule of GSK Biologicals' malaria vaccine RTS,S/AS01E with a fractional third dose at Month 2 compared to a standard schedule of RTS,S/AS01E with three full doses in terms of vaccine efficacy against clinical malaria (primary case definition) over 12 months post-Dose 3.
Clinicaltrials.g ov	Link

Glossary

Infectious diseases GSK4406371 (MMRV new strain vaccine)

Infectious diseases

Phase	Ι	
Patient	Healthy children 4-6 years of age	
Subjects	800	
	Investigational MMRV(H)NS vaccine	
Treatment	Investigational MM(H)RVNS vaccine	
arms	Investigational M(L)M(L)R(L)V(L)NS vaccine	
	Marketed MMRV_Lot 1 and Lot 2 vaccine	
Description	A single-blind, randomized, controlled trial to evaluate the immunogenicity and safety of a measles, mumps, rubella, varicella vaccine compared with ProQuad, administered in healthy children 4-6 years of age	
The star	Trial start: Q4 2022	
Timeline	Data anticipated: H2 2024	
Key end points	Anti-measles, anti-mumps, anti-rubella, and anti-glycoprotein H antibodies geometric mean concentrations	
Clinicaltrials.g ov	Link	

HIV

Infectious diseases GSK3536852 (Shigella)

Phase	1/11
Patient	Adults in Europe (Stage 1) followed by age de-escalation from adults to children and infants and dose finding in infants in Africa (Stage 2)
Subjects	550
	Drug: altSonflex Placebo (adults stage 1 in Europe)
	Biological: altSonflex1-2-3 High Dose C (adults stage 1 in Europe, adults, children and infants stage 2 in Africa)
	Biological: altSonflex1-2-3 Medium Dose B (children and infants stage 2 in Africa)
Treatment arms	Biological: altSonflex1-2-3 Low Dose A (infants stage 2 in Africa)
ums	Comparators: Menveo and Boostrix (adults stage 2 in Africa)
	Comparators: Menveo and Typhim Vi (children stage 2 in Africa)
	Comparators: Menveo and Infanrix (infants stage 2 in Africa)
Description	A staged observer-blind, randomised, controlled, multi-country trial to evaluate the safety, reactogenicity, and immune responses to the GVGH altSonflex1-2-3 vaccine against <i>S. sonnei</i> and <i>S. flexneri</i> serotypes 1b, 2a, and 3a, in adults in Europe (Stage 1) followed by age de-escalation from adults to children and infants, and dose-finding in infants in Africa (Stage 2)
Timeline	Trial start: Q4 2021
	Data anticipated: 2025
Key end points	Immune response to identify the preferred dose of each component of the altSonflex1-2-3 vaccine (low, medium, or high) for infants 9 months of age in Africa (Stage 2). To evaluate the safety and reactogenicity of the altSonflex1-2-3 vaccine in all participants in Europe and Africa (Stage 1 and Stage 2)
Clinicaltrials.g ov	Link



Glossary

Infectious diseases GSK3528869 (Chronic HBV infection)

Infectious diseases

Phase	1/11	
Patient	HBV suppressed subjects under nucleo(s)tide treatment	
Subjects	148	
	ChAd155-hli-HBV low dose formulation	MVA-HBV low dose formulation
Treatment	ChAd155-hli-HBV high dose formulation	MVA-HBV high dose formulation
arms	HBc-HBs/AS01B-4 low dose formulation	Placebo
	HBc-HBs/AS01B-4 high dose formulation	
Description	A first time in human trial on GSK's therapeutic vaccines to evaluate the reactogenicity, safety, immunogenicity and efficacy on reduction of serum HBV surface antigen in HBV suppressed subjects under nucleo(s)tide treatment.	
T!	Trial start: Q1 2019	
Timeline	Data anticipated: 2025	
Key end points	Safety and reactogenicity, as well as percentage of patients with >1 log decline of HBsAg	
Clinicaltrials.g ov	Link	

NCT04886154

HIV

Glossary

Infectious diseases GSK4023393 (MenABCWY, 2nd Gen)

Infectious diseases

1/11 Phase Healthy adults (phase I) and healthy adolescents and adults (phase II) Patient Subjects 1258 Combination Product: MenABCWY-2Gen low dose vaccine Combination Product: MenABCWY-2Gen high dose vaccine Treatment **Combination Product: Placebo** arms **Combination Product: MenB vaccine** Biological: MenACWY vaccine A randomised, controlled trial to assess the safety, effectiveness and immune response of meningococcal combined ABCWY vaccine when administered to Description healthy adults (phase I) and to healthy adolescents and adults (phase II) Trial start: Q2 2021 Timeline Data anticipated: H1 2024 AEs, including all SAEs, AEs leading to withdrawal and AEs of special interest (AESIs) Key end points Immunological vaccine effectiveness by enc-hSBA and immunogenicity by hSBA on indicator strains Clinicaltrials.g Link

NCT05082285

Phase	П		
Patient	Healthy infants		
Subjects	724		
	Combination Product: MenABCWY-2Gen low dose vaccine		
Treatment	Combination Product: MenABCWY-2Gen high dose vaccine		
arms	Combination Product: MenABCWY		
	Combination Product: MenB + MenACWY-TT		
Description	A randomised, partially blinded trial to assess the safety, tolerability and immunogenicity of meningococcal combined ABCWY vaccine when administered to healthy infants		
	Trial start: Q4 2021		
Timeline	Data anticipated: 2025		
Key end	AEs, including all SAEs, AEs leading to withdrawal and AEs of special interest (AESIs), medical attended events (MAE)		
points	Immunogenicity by hSBA to indicator strains		
Clinicaltrials.g ov	Link		

32

Glossary

Infectious diseases GSK4178116 (Varicella new strain)

Infectious diseases

Phase	II		
Patient	Healthy children between 12-15 months		
Subjects	800		
Treatment arms	Arm A: low potency varicella NS vaccine, plus routine schedule		
	Arm B: medium potency varicella NS vaccine, plus routine schedule		
	Arm C: high potency varicella NS vaccine, plus routine schedule		
	Arm D: marketed varicella vaccine lot 1, plus routine schedule		
	Arm E: marketed varicella vaccine lot 2, plus routine schedule		
Description	A observer-blind, randomised, controlled trial to evaluate the immunogenicity and safety of a varicella vaccine at various potencies compared with Varivax as a first dose, administered in healthy children in their second year of life		
Timeline	Trial start: Q4 2021		
	Data anticipated: H1 2024		
Key end points	Anti-glycoprotein-E antibodies at day 43		
Clinicaltrials.g ov	Link		

Glossary

Infectious diseases

GSK5101955 (Paediatric Pneumococcal disease, 24-valent)

HIV

Phase	II		
Patient	Healthy infants		
Subjects	760		
Treatment arms	Arm A: 1 mcg AFX3772 administered intramuscularly 4 times within 12 months Arm B: 2 mcg AFX3772 administered intramuscularly 4 times within 12 months		
	Arm C: 5 mcg AFX3772 administered intramuscularly 4 times within 12 months		
	Arm D: PCV13 administered intramuscularly 4 times within 12 months		
Description	A randomised, double-blind, multi-dose, dose finding trial to evaluate the safety, tolerability and immunogenicity of AFX3772 compared with PCV13 in healthy infants		
Timeline	Trial start: Q2 2022		
	Data anticipated: 2025		
Key end points	Safety, tolerability profiles of 3 different dose levels of AFX3772 compared with PCV13 with respect to the proportion of participants with AEs		
Clinicaltrials.g ov	Link		

Infectious diseases GSK4106647 (Human papillomavirus)

Infectious diseases

Phase	II	
Patient	Healthy females 16 to 26 years of age	
Subjects	1080	
Treatment arms	Arm A: HPV9 High formulation	
	Arm B: HPV9 Medium formulation	
	Arm C: HPV9 Low formulation	
	Arm D: Gardasil 9	
Description	A randomized, observer-blinded, multi-country trial to evaluate safety and immunogenicity of investigational adjuvanted Human Papillomavirus Vaccine in females (16 to 26 years of age)	
Timeline	Trial start: Q3 2022	
	Data anticipated: HI 2024	
Key end points	AEs, SAEs, anti-HPV IgG concentrations	
Clinicaltrials.g ov	Link	

Glossary

Infectious diseases GSK4348413 (Gonorrhoea)

Infectious diseases

Phase	1/11		
Patient	Healthy adults 18 to 50 years of age		
Subjects	774		
Treatment arms	Phase I	Phase II	
	NgG low dose investigational vaccine	NgG HTD investigational vaccine	
	NgG medium dose investigational vaccine	NgG below HTD investigational vaccine	
	NgG high dose investigational vaccine	Placebo	
	Placebo		
Description	An observer-blind, randomized, placebo-controlled multi-country trial to assess safety and efficacy of GSK <i>Neisseria gonorrhoeae</i> GMMA (NgG) investigational vaccine when administered to healthy adults 18 to 50 years of age		
Timeline	Trial start: Q4 2022		
	Data anticipated: 2025		
Key end	AEs and SAEs		
	Incidence rates of gonorrhoeae in trial phase II		
Clinicaltrials.g ov	Link		

NCT05446740

HIV

Glossary

Opportunity driven

Infectious diseases GSK4382276 (mRNA Seasonal Flu)

Infectious diseases

Phase Healthy younger and older adults Patient Subjects 324 GSK4382276A Dose level 1 GSK4382276A Dose level 7 GSK4382276A Dose level 2 GSK4382276A Dose level 8 Treatment GSK4382276A Dose level 3 GSK4382276A Dose level 9 arms GSK4382276A Dose level 4 Combination Product: FDQ21A-NH GSK4382276A Dose level 6 Combination Product: FDO22A-NH A randomized, observer-blind, dose-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an mRNA-based monovalent influenza Description vaccine candidate in healthy younger and older adults Trial start: Q3 2022 Timeline Final data anticipated: H1 2024 Safety and reactogenicity, including number of participants reporting systemic Key end and solicited administration site events points Serum anti-influenza seroconversion rates and geometric mean titers Clinicaltrials.g Link ov

Phase	1/11
Patient	Healthy younger and older adults
Subjects	1253
	Biological: Flu mRNA
Treatment arms	Combination Product: Control 1
	Combination Product: Control 2
Description	A randomized, dose-finding/dose-confirmation study to evaluate the reactogenicity, safety and immunogenicity of mRNA-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults
Timestine	Trial start: Q2 2023
Timeline	Final data anticipated: H2 2024
Key end points	Safety and reactogenicity, including number of participants reporting systemic and solicited administration site events
	Serum anti-influenza antigen seroconversion rates and geometric mean titers
Clinicaltrials.g ov	Link

Glossary

Infectious diseases GSK4396687 (mRNA COVID-19)

Infectious diseases

Phase	П
	···
Patient	Adults at least 18 years old
Subjects	415
	Arm A: CV0701 bivalent high dose
_	Arm B: CV0701 bivalent medium dose
Treatment arms	Arm C: CV0701 bivalent low dose
	Arm D: CV0601 monovalent high dose
	Arm E: Control vaccine
Description	A randomized, active-controlled, observer-blind study to assess the safety, reactogenicity, and immunogenicity of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults who previously received a complete primary vaccination series with or without booster dose(s)
Time e line e	Trial start: Q3 2023
Timeline	Data anticipated: H2 2024
Key end points	Serum neutralizing titers against pseudoviruses bearing SARS-CoV-2 spike proteins at Day 29
	Percentage of participants with solicited local AE during 7 days after vaccination
Clinicaltrials.g ov	Link

Infectious diseases

HIV

Infectious diseases GSK3993129 (CMV)

Phase	1/11	
Patient	Healthy adults 18 to 50 years of age	
Subjects	329	
	Arm A: pentamer (low)/gB(low)/adjuvant vaccine	
	Arm B: pentamer (med)/gB(low)/adjuvant vaccine	
Treatment arms	Arm C: pentamer (med)/gB(med)/adjuvant vaccine	
anno	Arm D: pentamer (high)/gB(med)/adjuvant vaccine	
	Arm F: placebo (saline)	
Description	A randomised, observer-blind, placebo-controlled, dose escalation trial to assess safety, reactogenicity and immunogenicity of a candidate CMV vaccine comprising recombinant protein and adjuvant	
— , ,,	Trial start: Q4 2021	
Timeline	Data anticipated: 2026+	
Key end points	Safety, reactogenicity and immunogenicity	
Clinicaltrials.g ov	Link	

Glossary

Infectious diseases GSK3943104 (Therapeutic HSV)

Infectious diseases

Phase	1/11	
Patient	Healthy participants aged 18-60 years negative for HSV-2	
Patient	HSV-2 and HSV-1 patients with \geq 3 episodes of GH in the previous	; year
Subjects	Part 1: 245; Part 2: 240	
	Arm A: non-adjuvanted HSV formulation 1 - part 1 group	Arm H: HSV formulation 2 with adjuvant 2 - part 1 group
	Arm B: non-adjuvanted HSV formulation 2 - part 1 group	Arm I: HSV formulation 3 with adjuvant 2 - part 1 group
	Arm C: non-adjuvanted HSV formulation 3 - part 1 group	Arm J: part 1 group (placebo)
Treatment arms	Arm D: HSV formulation 1 with adjuvant 1 - part 1 group	Arm K: selected formulation - part 2 group
	Arm E: HSV formulation 2 with adjuvant 1 - part 1 group	Arm L: selected formulation - part 2 group
	Arm F: HSV formulation 3 with adjuvant 1 - part 1 group	Arm M: part 2 group (placebo)
	Arm G: HSV formulation 1 with adjuvant 2 - part 1 group	
Description	An observer-blind, randomised, placebo-controlled, multi-country trial to evaluate reactogenicity, safety, immune response and efficacy of an HSV vaccine	
.	Trial start: Q1 2022	
Timeline	Data anticipated: 2026+	
Key end points	Part 1: Percentage of participants reporting each solicited administration site event; dose selection	
	Part 2: Clinical efficacy (TTFE)	
Clinicaltrials.g ov	Link	



Infectious diseases GSK4077164 (iNTS Typhimurium + Enteritidis)

Infectious diseases

Phase	Ι/ΙΙα		
Patient	Healthy European and African adults		
Subjects	155		
	Arm A: iNTS-TCV low dose group - Europe	Arm F: Step 2 group (placebo) - Europe	
	Arm B: iNTS-GMMA and TCV low doses group - Europe	Arm G: iNTS-TCV full dose_2 group - Africa	
Treatment arms	Arm C: Step 1 group (placebo) - Europe	Arm H: iNTS-GMMA and TCV full doses_2 group - Africa	
	Arm D: iNTS-TCV full dose_1 group - Europe	Arm I: Stage 2 group (control) - Africa	
	Arm E: iNTS-GMMA and TCV full doses_1 group - Europe		
Description	An observer-blind, randomised, controlled, two-stage, multi-country trial to evaluate the safety, reactogenicity and immune response of the trivalent vaccine against iNTS and Typhoid fever		
	Trial start: Q3 2022		
Timeline	Data anticipated: H2 2024		
Key end points	To evaluate the safety, reactogenicity and immunogenicity profile of iNTS-TCV vaccine in healthy European/African adults		
Clinicaltrials.g ov	Link		

Infectious diseases

Glossary

Infectious diseases GSK4077164 (iNTS S. typhimurium + S. enteritidis + S. Typhi)

HIV

Phase	lla	
Patient	Adults, children and infants, including dose-finding in infants in Africa (Ghana)	
Subjects	20 adults/40 children/60 infants 9 months/ 396 infants 6 weeks	
	Stage 1: Age-de-escalation	
	Adults (dose C or control)	
Treatment arms	Children (dose B or C or control)	
	Infants, 9 months (dose A, B, C or control)	
	Infants, 6 months (dose A, B, C, or control)	
	Stage 2: Dose finding in infants 6 weeks of age	
Description	An observer-blind, randomized, controlled, age-de-escalation, single center interventional study to evaluate the safety, reactogenicity, and immune response of the GVGH iNTS vaccine against <i>S. typhimurium</i> and <i>S. enteritidis</i> , in adults, children and infants, including dose-finding in infants, infants, infants, including dose-finding in infants, infants, including dose-finding in infants, infants, including dose-finding in infants, infants, including dose-finding infants, infants, including dose-finding infants, infants, infants, including dose-finding infants, infants, including dose-finding infants, infants, infants, including dose-finding infants, infants, including dose-finding infants, infan	
	Trial start: Q1 2024	
Timeline	Data anticipated: 2026+	
Key end points	To evaluate the safety, reactogenicity and immunogenicity profile of iNTS-GMMA vaccine in adults, children and infants (Ghana)	
Clinicaltrials.g ov	Link	

Glossary

Infectious diseases GSK3036656 (Tuberculosis)

Infectious diseases

NCT05382312

Phase	lla	
Patient	Males and females aged 18 to 65 years inclusive with drug-sensitive (rifampicin-susceptible) pulmonary tuberculosis	
Subjects	70	
	Arm A: Participants receiving GSK3036656+bedaquiline	
Treatment	Arm B: Participants receiving GSK3036656+delamanid	
arms	Arm C: Participants receiving bedaquiline+delamanid	
	Arm D: Participants receiving RIFAFOUR e-275	
Description	A parallel group, randomised, open-label, 4 treatment arm trial to assess the early bactericidal activity, safety and tolerability of oral GSK3036656 in combination with either oral delamanid or oral bedaquiline, oral delamanid in combination with oral bedaquiline, or standard of care in males and females aged 18 to 65 years inclusive with drug-sensitive (rifampicin-susceptible) pulmonary tuberculosis	
	Trial start: Q3 2022	
Timeline	Data anticipated: H2 2024	
Key end points	Change from baseline in log10 CFU of Mycobacterium tuberculosis	
Clinicaltrials.g ov	Link	

GSK

Infectious diseases

HIV

Infectious diseases

GSK3536867 (Salmonella typhoid + paratyphoid A)

I
Healthy adults aged 18-50 years in Europe
96
Arm A: Step 1a low dose without adjuvant group
Arm B: Step 1a control group
Arm C: Step 1b low dose with adjuvant group
Arm D: Step 1b control group
Arm E: Step 2 full dose without adjuvant group
Arm F: Step 2 full dose with adjuvant group
Arm G: Step 2 control group
An observer-blind, randomised, controlled, single-centre trial to evaluate the safety, reactogenicity and immune responses to an adjuvanted and non-adjuvanted conjugate vaccine against Salmonella Typhi and Salmonella Paratyphi A
Trial start: Q4 2022
Data anticipated: H1 2024
Percentage of participants with solicited administration-site events, systemic events, unsolicited adverse event and any serious adverse events after the first vaccination
Link



Infectious diseases GSK2556286 (Tuberculosis)

Infectious diseases

Phase	I
Patient	Healthy adults
Subjects	120
	Arm A: Part A - GSK2556286 with up to 11 cohorts
Treatment	Arm B: Part A - placebo
arms	Arm C: Part B - GSK2556286 with up to 4 cohorts
	Arm D: Part B - placebo
Description	A randomised, double blind (sponsor unblinded), placebo-controlled, first time in human trial to evaluate the safety, tolerability and pharmacokinetics of single and repeat oral doses and the food effect of GSK2556286
T : <i>V</i> :	Trial start: Q4 2020
Timeline	Data anticipated: H2 2024
Key end points	SAEs and non-SAEs
Clinicaltrials.g ov	Link

Infectious diseases GSK3494245 (Visceral leishmaniasis)

Infectious diseases

Phase	1	
Patient	Healthy adult males	
Subjects	54	
Treatment arms	Cohort 1: maximum of 3 ascending doses GSK3494245 starting at 20 mg and placebo (fasted)	
	Cohort 2: maximum of 3 ascending doses GSK3494245 starting at dose level 5 and placebo (fasted)	
	Cohort 3: Participants receiving GSK3494245 (fasted then fed)	
	Cohort 3: Participants receiving GSK3494245 (fed then fasted)	
Description	A randomized, double-blind, placebo-controlled, first time in human trial to evaluate the safety, tolerability and pharmacokinetics of single (in both fed and fasted states) doses of GSK3494245 in healthy participants	
	Trial start: Q3 2020	
Timeline	Data anticipated: H2 2024	
Key end points	Number of participants with AEs and SAEs	
Clinicaltrials.g ov	Link	

Glossary

Infectious diseases GSK4024484 (Malaria)

Infectious diseases

Phase	I	
Patient	Healthy adults aged 18-60 years	
Subjects	54	
Treatment arms	Group/Arm 2: 12mg SAD GSK'484 or placebo (fasted state) Group/Arm 3: 24mg SAD GSK'484 or placebo (fasted state) Group/Arm 4: 40mg SAD GSK'484 or placebo (fasted state) Group/Arm 5: 60mg SAD GSK'484 or placebo (fasted state) Group/Arm 5: 60mg SAD GSK'484 or placebo (fasted state)	/Arm 8: 100 mg SAD GSK'484 or matching placebo /Arm 9: Optional Group (dose escalation or dose level cation flexibility) /Arm 10: 10mg MAD GSK'484 or matching placebo /Arm 11: 20mg MAD GSK'484 or matching placebo /Arm 12: 30mg MAD GSK'484 or matching placebo
Description	A randomised, double-blind placebo-controlled, First Time in Human Study to evaluate the safety and pharmacokinetics of single and multiple oral doses and food effect of GSK4024484	
Timeline	Trial start: Q4 2023 Data anticipated: H2 2025	
Key end points	Number of participants with AEs and SAEs	
Clinicaltrials.g ov	Link	

Glossary

Infectious diseases GSK3923868 (Viral COPD exacerbations)

Infectious diseases

Phase	lb
Patient	Participants with mild asthma
Subjects	68
Treatment	Arm A: GSK3923868
arms	Arm B: placebo
Description	A randomised, double-blind, placebo controlled, repeat dose trial to assess the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled GSK3923868 during experimental human rhinovirus infection participants with mild asthma
Timeline	Trial start: Q2 2022
	Data anticipated: HI 2024
Key end points	AUC of CfB in LRTS score from day of inoculation up to discharge
Clinicaltrials.g ov	Link

Glossary

Infectious diseases GSK3965193 (Chronic HBV infection)

Infectious diseases

Phase	
Patient	Healthy participants and those living with chronic hepatitis B infection
Subjects	132
Treatment arms	Part 1 cohort 1: GSK3965193 and placebo Part 1 cohort 2: GSK3965193 and placebo Part 2A cohort 3: GSK3965193 or placebo Part 2A cohort 4: GSK3965193 or placebo Part 2A cohort 5: GSK3965193 or placebo Part 2B cohort 6: GSK3965193 Part 3 cohort 7: GSK3965193 or placebo Part 4 cohort 8: GSK3965193 and bepirovirsen or placebo and bepirovirsen
Description	Four-part, randomised, double-blind (Parts 1, 2A, 3 and 4), multi-centre, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK3965193 monotherapy in healthy participants and in participants living with chronic hepatitis B infection; and GSK3965193 in combination with bepirovirsen
Time a line a	Trial start: Q2 2022
Timeline	Data anticipated: 2026+
Key end points	Number of participants with AEs, SAEs, and withdrawals due to AEs Part 3: Change from Baseline in HBsAg levels Part 4 : Number of participants achieving sustained virologic response
Clinicaltrials.g ov	Link

Innovation: Pipeline growth	Infectious diseases	HIV	Respiratory/Immunology	Oncology	Opportunity driven	Glossary

Innovation: Pipeline growth

Opportunity driven

HIV VH3810109

NCT04871113 - B-NAB

Phase	П	Phase	llb
Patient	Anti-retroviral naïve HIV-1 infected adults	Patient	Antire
Subjects	62	Subjects	150
Treatment	Part 1 Cohort 1: '109A infusion (40mg/kg) Cohort 2: '109A infusion (280 mg/kg) Part 2	Treatment arms	Group Group Group antire
arms	Cohort 3: '109A IV or SC – dosing determined from part 1 Cohort 4: '109A IV or SC – dosing determined from part 1 Cohort 5: '109A IV or SC – dosing determined from part 1	Description	A mu and t subcu intrar
Description	A multicentre, randomised, open-label, two part adaptive design trial to evaluate the antiviral effect, safety and tolerability of GSK3810109A, an HIV-1 specific broadly neutralizing human monoclonal antibody in antiretroviral- naïve HIV-1-infected adults	Timeline	thera Trial s Data
Timeline	Trial start: Q2 2021 Data anticipated: H2 2023	Key end points	Safet
Key end points	Safety, plasma HIV-1 levels	Clinicaltrials.g ov	<u>Link</u>
Clinicaltrials.g ov	Link		
GSK			

Phase	llb
Patient	Antiretroviral therapy (ART)-experienced adults living with HIV
Subjects	150
	Group 1: VH3810109 + cabotegravir
Treatment	Group 2 VH3810109 + rHuPH20 + cabotegravir
arms	Group 3: Active comparator - Participants receiving standard of care (SOC) antiretroviral therapy (ART)
Description	A multicentre, randomised, open-label, trial comparing the efficacy, safety, PK, and tolerability of VH3810109, administered either intravenously or as a subcutaneous infusion with rHuPH20, in combination with cabotegravir given intramuscularly, to standard of care in virologically suppressed, antiretroviral therapy (ART)-experienced adults living with HIV
	Trial start: Q3 2023
Timeline	Data anticipated: H2 2024
Key end points	Safety, plasma HIV-1 levels
Clinicaltrials.g ov	Link

Innovation: Pipeline growth

Glossary

HIV VH3739937

NCT06061081		
Phase	П	
Patient	Treatment-naïve adults living with HIV-1	
Subjects	26	
Treatment arms	Arm A: VH3738837 Arm B: placebo	
Description	A randomized, double-blind (sponsor-unblinded), placebo-controlled, adaptive study to investigate the antiviral effect, safety, tolerability and pharmacokinetics of VH3739937 in treatment-naïve adults living with HIV-1	
Timeline	Trial start: Q1 2024	
Ilmeline	Data anticipated: H1 2024	
Key end points	AEs and SAEs, concentrations of VH3738837	
Clinicaltrials.g ov	Link	

Glossary

HIV VH4004280 & VH4011499

NCT06012136		
Phase	1	
Patient	Healthy adults	
Subjects	160	
Treatment arms	Arm A: VH4004280 Arm B: Placebo Arm C: VH4011499	
Description	A double-blind (sponsor-unblinded), placebo-controlled, randomized, single dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of a parenterally administered suspension of investigational capsid inhibitors in healthy adults	
T ime a I im a	Trial start: Q3 2023	
Timeline	Data anticipated: 2025+	
Key end points	AEs, PK	
Clinicaltrials.g ov	Link	

Phase	II
Patient	HIV-1 infected treatment-naïve adults
Subjects	42
Treatment arms	Arm A: VH4004280 Arm B: VH4011499 Arm C: VH4004280-matching placebo Arm D: VH4011499-matching placebo
Description	A randomized, double-blind (sponsor-unblinded), placebo-controlled trial to investigate the antiviral effect, safety, tolerability and pharmacokinetics of orally administered investigational capsid inhibitor monotherapy in HIV-1 infected treatment-naïve adults
Timeline	Trial start anticipated: H2 2023 Data anticipated: H1 2024
Key end points	Maximum change from baseline (Day 1) in plasma HIV-1 RNA
Clinicaltrials.g ov	Link

Innovation: Pipeline growth

Glossary

HIV VH4524184

Phase	lla
Patient	HIV-1 infected treatment naïve adults
Subjects	28
Treatment arms	Arm A: VH4524184 Arm B: Placebo
Description	A randomized, double-blind (sponsor unblinded), placebo-controlled study to investigate the antiviral effect, safety, tolerability and pharmacokinetics of VH4524184 in HIV-1 infected treatment naïve adults
Timeline	Trial start anticipated: H1 2024 Data anticipated: H2 2024
Key end points	Maximum change from baseline in log10 plasma HIV-1 RNA
Clinicaltrials.g ov	Link

Glossary

HIV cabotegravir

NCT05418868		NCT06033547		
Phase	I	Phase	Ι	
Patient	Healthy adult volunteers	Patient	Healthy adult volunteers	
Subjects	60	Subjects	48	
Treatment arms	Part A: Participants receiving CAB 200 mg/mL with rHuPH20 Part C: Participants receiving CAB 400 mg/mL	Treatment arms	Part A: Participants receiving cabotegravir Formulation F Part B: Participants receiving cabotegravir Formulation G	
	Part D: Participants receiving CAB 400 mg/mL with rHuPH20 A multi-centre, open-label, single dose escalation trial to evaluate the pharmacokinetics, safety and tolerability of long-acting cabotegravir co-	_ Description	An open-label, single dose escalation study to evaluate the pharmacokinetics, safety and tolerability of two different formulations of long-acting cabotegravir administered to healthy adult participants	
Description	administered with recombinant human hyaluronidase PH20 (rHuPH20) in healthy adult volunteers	Timeline	Trial start: Q3 2023	
	Trial start: Q2 2022		Data anticipated: 2025	
Timeline	ata anticipated: H1 2024 Key end points		Plasma concentrations of cabotegravir	
Key end points	Plasma concentrations of cabotegravir	Clinicaltrials.g ov	Link	
Clinicaltrials.g ov	Link			

GSK

Respiratory/Immunology

Opportunity driven

Respiratory/Immunology Nucala (mepolizumab)

NCT04133909 - MATINEE

Phase	III
Patient	Participants with chronic obstructive pulmonary disease (COPD) experiencing frequent exacerbations and characterised by eosinophil levels
Subjects	806
Treatment	Arm A: placebo
arms	Arm B: mepolizumab
Description	A multicentre randomised, double-blind, parallel-group, placebo-controlled trial of mepolizumab 100 mg subcutaneously as add-on treatment in participants with COPD experiencing frequent exacerbations and characterised by eosinophil levels
Timeline	Trial start: Q4 2019
IImeline	Data anticipated: H2 2024
Key end points	Annualised rate of moderate or severe exacerbations
Clinicaltrials.g ov	Link

Respiratory/Immunology depemokimab

NCT04719832 - SWIFT-1

Phase	Ш
Patient	Adult and adolescents with severe uncontrolled asthma with an eosinophilic phenotype
Subjects	395
Treatment	Arm A: depemokimab plus SoC
arms	Arm B: placebo plus SoC
Description	A 52-week, randomised, double-blind, placebo-controlled, parallel-group, multi-centre trial of the efficacy and safety of depemokimab adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype
Timeline	Trial start: Q1 2021
Imeline	Data anticipated: H1 2024
Key end points	Annualised rate of clinically significant exacerbations over 52 weeks
Clinicaltrials.g ov	Link

NCT04718103 - SWIFT-2

Phase	III
Patient	Adult and adolescents with severe uncontrolled asthma with an eosinophilic phenotype
Subjects	397
Treatment	Arm A: depemokimab plus SoC
arms	Arm B: placebo plus SoC
Description	A 52-week, randomised, double-blind, placebo-controlled, parallel-group, multi-centre trial of the efficacy and safety of depemokimab adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype
Timestine	Trial start: Q1 2021
Timeline	Data anticipated: H1 2024
Key end points	Annualised rate of clinically significant exacerbations over 52 weeks
Clinicaltrials.g ov	Link

Opportunity driven

Respiratory/Immunology depemokimab

NCT05243680 - AGILE

Phase	III
Patient	Adult and adolescents with severe asthma with an eosinophilic phenotype from studies SWIFT-1 and SWIFT-2
Subjects	637
Treatment arms	Participants diagnosed with asthma receiving depemokimab
Description	A 52-week, open label extension phase of SWIFT-1 and SWIFT-2 to assess the long-term safety and efficacy of depemokimab adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype
Timeline	Trial start: Q1 2022
l imeline	Data anticipated: 2025
Key end points	Number of participants with AEs and SAEs and incidence of immunogenicity over 52 weeks
Clinicaltrials.g ov	Link

NCT04718389 - NIMBLE

Phase	III
Patient	Adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with depemokimab compared with mepolizumab or benralizumab
Subjects	1700
Treatment	Arm A: participants receiving depemokimab plus placebo matching prior anti-IL-5/5R treatment
arms	Arm B: participants receiving prior anti-IL-5/5R treatment plus placebo matching depemokimab
Description	A 52-week, randomised, double-blind, double-dummy, parallel group, multi- centre, non-inferiority trial assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with depemokimab compared with mepolizumab or benralizumab
Time	Trial start: Q1 2021
Timeline	Data anticipated: 2025
Key end points	Annualised rate of clinically significant exacerbations over 52 weeks
Clinicaltrials.g ov	Link

Opportunity driven

NCT05274750 - ANCHOR-1

HIV

Glossary

Respiratory/Immunology depemokimab

Phase	III
Patient	Adults with chronic rhinosinusitis with nasal polyps (CRSwNP)
Subjects	276
Treatment	Arm A: depemokimab
arms	Arm B: placebo
Description	A randomized, double-blind, parallel group trial to assess the efficacy and safety of 100 mg subcutaneous depemokimab in patients with CRSwNP
Timesline	Trial start: Q2 2022
Timeline	Data anticipated: H2 2024
Key end points	Change from baseline in total endoscopic nasal polyps (NP) score at week 52
	Change from baseline in mean nasal obstruction verbal response scale (VRS) score from Week 49 through to Week 52
Clinicaltrials.g ov	Link

NCT05281523 - ANCHOR-2

Phase	III
Patient	Adults with chronic rhinosinusitis with nasal polyps (CRSwNP)
Subjects	264
Treatment	Arm A: depemokimab
arms	Arm B: placebo
Description	A randomized, double-blind, parallel group trial to assess the efficacy and safety of 100 mg subcutaneous depemokimab in patients with CRSwNP
T ime a I im a	Trial start: Q2 2022
Timeline	Data anticipated: H2 2024
	Change from baseline in total endoscopic nasal polyps (NP) score at week 52
Key end points	Change from baseline in mean nasal obstruction verbal response scale (VRS) score from Week 49 through to Week 52
Clinicaltrials.g ov	Link

Respiratory/Immunology depemokimab

NCT05263934 - OCEAN

Phase	III
Patient	Adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA) receiving standard of care therapy
Subjects	160
Treatment	Arm A: depemokimab + placebo matching mepolizumab
arms	Arm B: mepolizumab + placebo matching depemokimab
Description	A 52-week randomised, double-blind, double-dummy, parallel-group, multicentre, non-inferiority trial to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving standard of care therapy
Time a line	Trial start: Q3 2022
Timeline	Data anticipated: 2025
Key end points	Number of participants with remission
Clinicaltrials.g ov	Link

NCT05334368 - DESTINY

Phase	III
Patient	Adults with hypereosinophilic syndrome (HES) receiving standard of care therapy
Subjects	120
Treatment	Arm A: depemokimab
arms	Arm B: placebo
Description	A randomised, double-blind, placebo-controlled trial to investigate the efficacy and safety of depemokimab in adults with HES
Time a line a	Trial start: Q3 2022
Timeline	Data anticipated: 2026+
Key end points	Frequency of HES flares
Clinicaltrials.g ov	Link

Opportunity driven

Glossary

camlipixant

NCT05599191 - CALM-1

111
Adult participants with refractory chronic cough, including unexplained chronic cough
825
Arm A: camlipixant 25 mg twice a day
Arm B: camlipixant 50 mg twice a day
Placebo twice a day
A 52-week, randomised, double-blind, placebo-controlled, parallel-arm efficacy and safety study with open-label extension of camlipixant in adult participants with refractory chronic cough, including unexplained chronic cough
Trial start: Q4 2022
Data anticipated: 2025
24-hour cough frequency
Link

NCT05600777 - CALM-2

Phase	III
Patient	Adult participants with refractory chronic cough, including unexplained chronic cough
Subjects	825
	Arm A: camlipixant 25 mg twice a day
Treatment arms	Arm B: camlipixant 50 mg twice a day
	Placebo twice a day
Description	A 24-week, randomised, double-blind, placebo-controlled, parallel-arm efficacy and safety study with open-label extension of camlipixant in adult participants with refractory chronic cough, including unexplained chronic cough
Timeline	Trial start: Q1 2023
limeline	Data anticipated: 2025
Key end points	24-hour cough frequency
Clinicaltrials.g ov	Link

Opportunity driven

Respiratory/Immunology Benlysta (belimumab)

Phase	11/111
Patient	Adults with systemic sclerosis associated interstitial lung disease (SSc-ILD)
Subjects	300
Treatment arms	Arm A: belimumab + standard therapy
	Arm B: placebo + standard therapy
Description	A randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with SSc-ILD
Timeline	Trial start: Q4 2023
	Data anticipated: 2026+
Key end points	Absolute change from baseline in Forced Vital Capacity (FVC) millilitre (mL) at week 52
Clinicaltrials.g ov	Link

Glossary

Opportunity driven

Respiratory/Immunology GSK3858279 (Osteoarthritis pain)

NCT05838755 - NEPTUNE-17

Phase	II
Patient	Adult participants with chronic diabetic peripheral neuropathic pain (DPNP)
Subjects	240
	Arm A: GSK3858279 dose 1
Treatment arms	Arm B: GSK3858279 dose 2
Gims	Arm C: placebo
Description	A multicentre randomised, double-blind, placebo-controlled trial to evaluate efficacy, safety, tolerability, pharmacokinetics and target engagement of GSK3858279 in adult participants with chronic DPNP
	Trial start: Q4 2023
Timeline	Data anticipated: 2025
Key end points	Change from baseline in the weekly average of average daily pain intensity at week 12, assessed on Numeric Rating Scale (NRS)
Clinicaltrials.g ov	Link

NCT05838742 - MARS-17

Phase	П
Patient	Adult participants with moderate to severe pain due to knee osteoarthritis
Subjects	420
	Arm A: GSK3858279 dose 1
	Arm B: GSK3858279 dose 2
Treatment arms	Arm C: GSK3858279 dose 3
units.	Arm D: GSK3858279 dose 4
	Arm E: placebo
Description	A multicentre randomised, double-blind, placebo controlled, dose-finding trial of GSK3858279 in adult participants with moderate to severe pain due to knee osteoarthritis
	Trial start anticipated: H2 2023
Timeline	Data anticipated: 2025
Key end points	Change from baseline in the weekly average of average daily knee pain intensity at week 12, assessed on Numeric Rating Scale (NRS)
Clinicaltrials.g ov	Link

Respiratory/Immunology GSK1070806 (Atopic dermatitis)

Phase	llb
Patient	Patients with moderate to severe atopic dermatitis
Subjects	175
	Arm A: GSK1070806 dose 1
	Arm B: GSK1070806 dose 2
Treatment arms	Arm C: GSK1070806 dose 3
	Arm D: GSK1070806 dose 4
	placebo
Description	A randomized, double-blind, parallel group, placebo-controlled dose finding study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK1070806 SC injection
Timeline	Trial start: Q4 2023
	Data anticipated: 2025
Key end points	Percent change from baseline in eczema area and severity index (EASI) at Week 16
Clinicaltrials.g ov	Link

Glossary

Respiratory/Immunology GSK3888130 (Autoimmune disease)

Phase	I
Patient	Healthy participants aged 18-55 inclusive
Subjects	54
Treatment arms	Cohort 1: GSK3888130B at dose level 1 (placebo comparator) Cohort 2: GSK3888130B at dose level 2 (placebo comparator) Cohort 3: GSK3888130B at dose level 3 (placebo comparator) Cohort 4: GSK3888130B at dose level 4 (placebo comparator) Cohort 5: GSK3888130B at dose level 5 (placebo comparator) Cohort 6: GSK3888130B at dose level 5 (placebo comparator) Cohort 7: GSK3888130B at dose level 7 (placebo comparator)
Description	A randomised, double-blind, placebo controlled, single dose escalation trial to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of GSK3888130B
Timeline	Trial start: Q4 2021 Trial end: Q4 2023
Key end points	Number of participants with AEs and SAEs
Clinicaltrials.g ov	Link

Glossary

Respiratory/Immunology GSK3862995 (COPD)

Phase	I
Patient	Part A: Healthy participants Part B: Participants with Chronic Obstructive Pulmonary Disorder
Subjects	130
	Part A: Single ascending dose (SAD) of GSK3862995B
Treatment arms	Part B, arm A: Repeat doses GSK3862995B
	Part B, arm B: Placebo
Description	A two-part randomized, double-blind, placebo-controlled study to investigate safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of GSK3862995B following single ascending doses in healthy participants and repeat doses in participants with Chronic Obstructive Pulmonary Disease (COPD)
Timeline	Trial start: Q4 2023
Timeline	Data anticipated: 2026+
Key end points	AEs and SAEs
Clinicaltrials.g ov	Link

Glossary

68

Respiratory/Immunology GSK4347859 (Systemic lupus erythematosus)

NCT06188507

GSK

Phase	I
Patient	Healthy participants
Subjects	44
	Part 1, cohort 1: GSK4347859 or placebo
	Part 1, cohort 2: GSK4347859 or placebo
Treatment arms	Part 2, cohort 3: GSK4347859 (dose level A) or placebo
anns	Part 2, cohort 4: GSK4347859 (dose level B) or placebo
	Part 2, cohort 5: GSK4347859 (dose level C) or placebo
Description	A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK3996401 following single and multiple ascending doses of GSK4347859 in healthy participants
	Trial start: Q1 2024
Timeline	Data anticipated: 2025
Key end points	AEs and SAEs Maximum observed plasma concentration (Cmax) of GSK3996401 following administration of GSK4347859
Clinicaltrials.g ov	Link

Oncology				Oncoloav	

Glossary

Oncology Ojjaara/Omjjara (momelotinib)

Phase	II
Patient	Participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF)
Subjects	237
	Arm A: Study GS-US-352-0101
Treatment	Arm B: Study GS-US-352-1214
arms	Arm C: Study GS-US-352-1154
	Arm D: Study SRA-MMB-301
Description	Extended access and assess long-term safety of momelotinib (MMB) in participants with PMF or post-PV/ET MF
 . ,.	Trial start: Q3 2018
Timeline	Anticipated trial end: 2026+
Key end points	Number of patients who had access to and received the intervention
Clinicaltrials.g ov	Link

Oncology Jemperli (dostarlimab)

NCT03981796 -	RUBY ENGOT	-EN6 GOG- <mark>303</mark> 1
---------------	-------------------	------------------------------

Phase	III
Patient	Patients with recurrent or primary advanced endometrial cancer
Subjects	785
	Arm A: dostarlimab + SoC followed by dostarlimab
Treatment	Arm B: placebo + SoC followed by placebo
arms	Arm C: dostarlimab + SoC followed by dostarlimab+niraparib
	Arm D: placebo (+chemo) followed by PBO
Description	A randomised, double-blind, multi-centre trial of dostarlimab plus carboplatin- paclitaxel with and without niraparib maintenance versus placebo plus carboplatin-paclitaxel in patients with recurrent or primary advanced endometrial cancer
T 1	Trial start: Q3 2019
Timeline	Part 1 data reported: Q4 2022; Part 2 data reported: Q4 2023
Key end	Part 1: PFS by IA (dMMR/MSI-H and ITT) and OS (ITT)
points	Part 2: PFS (ITT)
Clinicaltrials.g ov	Link

NCT04581824 - PERLA

Phase	II
Patient	Participants with metastatic non-squamous non-small cell lung cancer (NSCLC)
Subjects	244
Treatment arms	Arm A: dostarlimab + chemotherapy Arm B: pembrolizumab + chemotherapy
Description	A randomised, double-blind trial to evaluate the efficacy of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy in metastatic non-squamous NSCLC
Timeline	Trial start: Q4 2020 Primary data reported: Q4 2022
Key end points	ORR, OS, PFS
Clinicaltrials.g ov	Link

Opportunity driven

Oncology Jemperli (dostarlimab)

NCT02715284 - GARNET

Phase	1/11
Patient	Participants with advanced solid tumors
Subjects	740
	Part 1: dostarlimab at ascending weight doses
	Part 2A: dostarlimab fixed dose of 500mg Q3W or 1000mg administered Q6W dose
Treatment	Part 2B: Cohort A1 dMMR/MSI-H endometrial
arms	Part 2B: Cohort A2 MMR proficient/MSS endometrial
	Part 2B: Cohort E: NSCLC
	Part 2B: Cohort F non-endometrial dMMR/MSI-H & POLE-mutation
	Part 2B: Cohort G PROC without known BRCA
Description	A multi-centre, open-label, first-in-human trial evaluating dostarlimab in participants with advanced solid tumors who have limited available treatment options
	Trial start: Q1 2016
Timeline	Primary data reported: Q1 2019
Key end points	ORR, DoR, safety
Clinicaltrials.g ov	Link
GSK	

NCT05723562 - AZUR-1

Phase	II
Patient	Patients with untreated stage II/III mismatch repair deficient/high microsatellite instability (dMMR/MSI-H) locally advanced rectal cancer
Subjects	150
Treatment arms	dostarlimab monotherapy
Description	A single-arm, open-label trial with dostarlimab monotherapy in participants with untreated stage II/III dMMR/MSI-H locally advanced rectal cancer
Timeline	Trial start: Q1 2023
	Data anticipated: 2026+
Key end points	Sustained cCR for 12, 24 and 36 months, EFS at 3 years
Clinicaltrials.g ov	Link

72

Opportunity driven

Oncology Jemperli (dostarlimab)

NCT05855200 - AZUR-2

Phase	III
Patient	Participants with untreated T4N0 or Stage III (resectable), mismatch repair deficient/high microsatellite instability (dMMR/MSI-H) colon cancer
Subjects	זוז
Treatment arms	Arm A: dostarlimab Arm B: Standard of care (FOLFOX/CAPEOX) or expectant observation post surgery.
Description	An open-label, randomized trial of perioperative dostarlimab monotherapy versus standard of care in participants with untreated T4N0 or Stage III dMMR/MSI-H resectable colon cancer
Timeline	Trial start: Q3 2023
	Data anticipated: 2026+
Key end points	EFS assessed by Blinded Independent Central Review (BICR)
Clinicaltrials.g ov	Link

Oncology Zejula (niraparib)

NCT03602859 - FIRST

Phase	ш
Patient	Participants with Stage III or IV nonmucinous epithelial ovarian cancer
Subjects	1402
Treatment arms	Arm A: SOC (carboplatin + paclitaxel ± bevacizumab) +placebo Arm B: SOC + niraparib Arm C: SOC + dostarlimab + niraparib
Description	A randomised, double-blind comparison of platinum-based therapy with TSR- 042 and niraparib versus standard of care platinum-based therapy as first-line treatment of Stage III or IV nonmucinous epithelial ovarian cancer
Time aliana	Study start: Q4 2018
Timeline	Data anticipated: H1 2024
Key end points	PFS for PD-L1 positive participants. Primary analysis is ARM B vs ARM C. This is an adaptive study with ARM A closed post topline.
Clinicaltrials.g ov	Link

NCT04475939 - ZEAL-1L

Phase	III
Patient	Participants whose disease has remained stable or responded to 1L platinum based chemo with pembrolizumab for stage IIIB/IIIC or IV NSCLC
Subjects	666
Treatment arms	Arm A: niraparib plus pembrolizumab Arm B: placebo plus pembrolizumab
Description	A randomised, double-blind, placebo-controlled, multicentre study comparing niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy
Timeline	Study start: Q4 2020
	Data anticipated: H2 2024
Key end points	OS, PFS assessed by BICR using Response Evaluation Criteria in Solid Tumors (RECIST)
Clinicaltrials.g ov	Link

Opportunity driven

Oncology *Blenrep* (belantamab mafodotin)

NCT04126200 - DREAMM-5

Phase	1/11
Patient	Participants with relapsed/refractory multiple myeloma (RRMM)
Subjects	464
	Substudy 1: belantamab mafodotin + OX40 (GSK3174998)
	Substudy 2: belanatamab mafodotin + feladilimab
	Substudy 3: belantamab mafodotin + nirogacestat (GSI)
Treatment	Substudy 4: belantamab mafodotin + dostarlimab
arms	Substudy 5: belantamab mafodotin + isatuximab
ums	Substudy 6: belantamab mafodotin + nirogacestat + lenalidomide + dexamethasone
	Substudy 7: belantamab mafodotin + nirogacestat + pomalidomide + dexamethasone
Description	A randomised, open-label platform trial utilizing a master protocol to trial belantamab mafodotin as monotherapy and in combination with anti-cancer treatments
	Trial start: Q4 2019
Timeline	Data anticipated: 2026+
Key end points	Dose escalation phase: DLT, safety, ORR Cohort expansion phase: ORR, CBR, safety
Clinicaltrials.g ov	Link

NCT03544281 - DREAMM-6

Phase	1/11
Patient	Participants with relapsed/refractory multiple myeloma (RRMM)
Subjects	152
Treatment	Arm A: belantamab mafodotin + lenalidomide + dexamethasone
arms	Arm B: belantamab mafodotin + bortezomib + dexamethasone
Description	An open-label, dose escalation and expansion trial to evaluate safety, tolerability and clinical activity of the antibody-drug conjugate belantamab mafodotin administered in combination with lenalidomide plus dexamethasone (Arm A), or bortezomib plus dexamethasone (Arm B)
T '	Trial start: Q3 2018
Timeline	Data anticipated: H1 2024
Key end points	DLT, safety, ORR, PK
Clinicaltrials.g ov	Link

75

Glossary

Oncology *Blenrep* (belantamab mafodotin)

NCT04246047 - DREAMM-7

Phase	Ш
Patient	Participants with relapsed/refractory multiple myeloma (RRMM)
Subjects	571
Treatment	Arm A: belantamab mafodotin + bortezomib + dexamethasone (B-Vd)
arms	Arm B: daratumumab, bortezomib + dexamethasone (D-Vd)
Description	A multicentre, open-label, randomised trial to evaluate the efficacy and safety of the combination of belantamab mafodotin, bortezomib and dexamethasone (B-Vd) compared with the combination of daratumumab, bortezomib and dexamethasone (D-Vd)
Tine alia a	Trial start: Q2 2020
Timeline	Data readout: Q4 2023
Key end points	PFS, CRR, ORR, DoR, TTR, TTP, OS, PFS2, MRD negativity rate, safety
Clinicaltrials.g ov	Link

NCT04246047 - DREAMM-8

Phase	III
Patient	Participants with relapsed/refractory multiple myeloma (RRMM)
Subjects	300
Treatment	Arm A: belantamab mafodotin+ pomalidomide + dexamethasone (B-Pd)
arms	Arm B: Pomalidomide, bortezomib + dexamethasone (P-Vd)
Description	A multicentre, open-label, randomised trial to evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (B-Pd) versus pomalidomide plus bortezomib and dexamethasone (PVd)
Timeline	Trial start: Q4 2020
Ilmeline	Data anticipated: H2 2024
Key end points	PFS, MRD negativity rate, ORR, CRR, VGPR or better rate, DoR, TTBR, TTR, TTP, OS, PFS2, safety
Clinicaltrials.g ov	Link

Oncology *Blenrep* (belantamab mafodotin)

NCT04091126 - DREAMM-9

Phase	1
Patient	Patients with newly diagnosed multiple myeloma (MM)
Subjects	144
	Belantamab mafodotin, selected doses
Treatment arms	Bortezomib, administered subcutaneously or intravenously approximately 1 hour after the belantamab mafodotin infusion until Cycle 8
	Lenalidomide, administered as 25 or 10 mg orally, depending upon renal function.
	Dexamethasone, administered orally as 20 mg in cycles 1-8 and 40 mg in Cycle 9 onwards
Description	A randomised, dose and schedule evaluation trial to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin administered in combination with standard of care
T ime a li me	Trial start: Q4 2019
Timeline	Data anticipated: 2025
Key end points	DLT, safety, RDI of lenalidomide and bortezomib, PK, PD, ORR, CRR, VGPR or better
Clinicaltrials.g ov	Link

NCT04398745 - DREAMM-12

Phase	I
Patient	Relapsed/refractory multiple myeloma (RRMM) who have normal and varying degrees of impaired renal function
Subjects	36
Treatment arms	belantamab mafodotin monotherapy
Description	A trial to evaluate the pharmacokinetics and safety of belantamab mafodotin monotherapy
T :	Trial start: Q4 2020
Timeline	Data anticipated: 2025
Key end points	PK, change in vital signs, safety
Clinicaltrials.g ov	Link

Oncology *Blenrep* (belantamab mafodotin)

NCT04398680 - DREAMM-13

Phase	I
Patient	Relapsed/refractory multiple myeloma (RRMM) who have normal and impaired hepatic function
Subjects	28
Treatment arms	belantamab mafodotin monotherapy
Description	A trial to evaluate the pharmacokinetics and safety of belantamab mafodotin monotherapy in participants who have normal and impaired hepatic function
Timeline	Trial start: Q2 2021
	Data anticipated: 2025
Key end points	PK, change in vital signs, safety
Clinicaltrials.g ov	Link

NCT05064358 - DREAMM-14

Phase	II
Patient	Participants with relapsed/refractory multiple myeloma (RRMM)
Subjects	180
Treatment arms	Arm A: belantamab mafodotin
Description	A randomised, parallel, open-label study to investigate the safety, efficacy and pharmacokinetics of various dosing regimens of single-agent belantamab mafodotin (GSK2857916)
Timeline	Study start: Q1 2022 Data anticipated: H2 2024
Key end points	% of patients with >= Gr 2 ocular events, safety, ORR, TTR, DoR, TTP, PFS, OS
Clinicaltrials.g ov	Link

Opportunity driven

Oncology cobolimab

NCT04655976 - COSTAR LUNG

Phase	11/111
Patient	Patients with advanced non-small cell lung cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy
Subjects	750
	Arm A: cobolimab + dostarlimab + docetaxel
Treatment arms	Arm B: dostarlimab + docetaxel
Ginis	Arm C: docetaxel
Description	A randomised, open label trial comparing cobolimab + dostarlimab + docetaxel to dostarlimab + docetaxel to docetaxel alone
	Trial start: Q4 2020
Timeline	Data anticipated: H2 2024
Key end points	OS, ORR, PFS, D₀R, TTD
Clinicaltrials.g ov	Link

Glossary

Oncology belrestotug

NCT05565378 - GALAXIES LUNG-201

Phase	II		
Patient	Participants with previously untreated, locally advanced/metastatic, Programmed Death Ligand 1-selected non small cell lung cancer (NSCLC)		
Subjects	ects 300		
	Comparator Arm: pembrolizumab monotherapy		
	Intervention Arm: dostarlimab monotherapy		
Treatment	Substudy 1A: dostarlimab + belrestotug (Dose A)		
arms	Substudy 1B: dostarlimab + belrestotug (Dose B)		
	Substudy 1C: dostarlimab + belrestotug (Dose C)		
	Substudy 2: dostarlimab + belrestotug + GSK6097608		
Description	A randomized, open-label, platform trial utilizing a master protocol to evaluate novel immunotherapy combinations in participants with previously untreated, locally advanced/metastatic, Programmed Death Ligand 1-selected NSCLC		
Timeline	Trial start: Q4 2022		
Imeline	Data anticipated: 2026+		
Key end points	ORR		
Clinicaltrials.g ov	Link		

NCT06062420 - GALAXIES H&N-202

Phase	II			
Patient	Participants with recurrent/metastatic PD-L1 positive squamous cell carcinoma of the head and neck			
Subjects	ts 360			
	Arm A: dostarlimab monotherapy			
Treatment	Arm B: dostarlimab and belrestotug			
arms	Arm C: dostarlimab and GSK6097608			
	Arm D: dosarlimab and belrestotug and GSK6097608			
Description	A randomized, open-label, platform study using a master protocol to evaluate novel immunotherapy combinations as first-line treatment in participants with recurrent/metastatic PD-L1 positive squamous cell carcinoma of the head and neck			
Timeline	Trial start: Q4 2023			
Timeline	Data anticipated: 2026+			
Key end points	ORR			
Clinicaltrials.g ov	Link			

Innovation: Pipe	eline growth Infectious diseases	HIV	Respiratory/Immunology	Oncology	Opportunity driven	Glossary
Onco belrest	logy			•		
perrest	olug					
NCT03739710 -	– ENTRÉE					
Phase	II					
Patient	Participants with non-small cell lung co	incer (NSCLC)				
Subjects	185					
Treatment arms	Part 1 Arm A: feladilimab + ipilimumab Arm B: dostarlimab + GSK4428859A Arm C: dostarlimab + GSK4428859A + GSK6097608	Part 2 SoC: docetaxel feladilimab and docetaxel				
Description	A randomized, open-label platform tria novel regimens versus standard of care					
Timeline	Trial start: Q1 2019 Data anticipated: 2025+					
Key end points	Part 1: Number of participants with AEs changes in vital signs, physical examina Number of participants requiring dose	ation and laboratory parameter				
	Part 2: Overall survival					
Clinicaltrials.g ov	<u>Link</u>					

Glossary

Oncology GSK4381562

NCT05277051	ICT05277051				
Phase	I				
Patient	Participants with selected advanced solid tumors				
Subjects	162				
	Arm A: GSK4381562 monotherapy				
Treatment arms	Arm B: GSK4381562 plus dostarlimab				
	Arm C: GSK4381562 plus dostarlimab plus belrestotug				
Description	An open-label study of GSK4381562 administered as monotherapy and in combination with anticancer agents				
Timeline	Study start: Q1 2022				
Ilmeline	Data anticipated: 2026+				
Key end points	Safety and PK				
Clinicaltrials.g ov	Link				

Glossary

Oncology GSK6097608

NCT04446351	NCT04446351				
Phase	1				
Patient	<i>tient</i> Participants with advanced solid tumours				
Subjects	184				
	Arm A: GSK6097608				
	Arm B: GSK6097608 + dostarlimab				
Treatment	Arm C: dostarlimab				
arms	Arm D: dostarlimab + belrestotug				
	Arm E: dostarlimab + belrestotug + GSK6097608				
	Arm D: dostarlimab + cobolimab				
Description	A first time in human, open-label trial of GSK6097608 administered as monotherapy and in combination with anticancer agents				
The stines	Trial start: Q1 2020				
Timeline	Data anticipated: 2025				
Key end points	DLT, AEs and SAEs				
Clinicaltrials.g ov	Link				

Proceedings build of the second of	Glossary	iven	Opportunity o	Oncology	Respiratory/Immunology	HIV	Infectious diseases	eline growth	Innovation: Pip
NCT05714839 - DREAMM-20 Phase I/II Patient Relapsed/refractory multiple myeloma (RRMM) [Parts 1 and 2] Transplant-ineligible newly diagnosed multiple myeloma (TI NDMM) [Part 3] Subjects I24 Treatment arms Part 1: belantamab (may switch to belantamab mafodotin in case of PD) Part 2: Bela-xRd and Belamaf-xRd. The combination treatment xRd includes lenalidomide (R) and dexamethasone (d). x will be either a standard of care (SoC) or an emerging treatment. Part 3: Participants with TI NDMM will receive Bela-xRd and Belamaf-xRd. The combination treatment are for a standard of care (SoC) or an emerging treatment. Description An open-lab multicentre, dose escalation and expansion trial to investigate the safety, tolerability and clinical activity of belantamab as monotherapy and in combination with other treatments in participants with multiple myeloma Timeline Trial start: Q3 2023 Data anticipates: 2026+ Key end points Part 1: Safety and tolerability, PK and recommended Part 2 dose Part 2: Safety and tolerability, PK and recommended Part 2 dose Part 2: Safety and tolerability, PK and recommended Part 2 dose				•				logy	Onco
NCT05714839 - DREAMM-20 Phase I/II Patient Relapsed/refractory multiple myeloma (RRMM) [Parts 1 and 2] Transplant-ineligible newly diagnosed multiple myeloma (TI NDMM) [Part 3] Subjects I24 Freatment Part 1: belantamab (may switch to belantamab mafodotin in case of PD) Part 2: Bela-xRd and Belamaf-xRd. The combination treatment xRd includes lenalidomide (R) and dexamethasone (d). x will be either a standard of care (SoC) or an emerging treatment. Part 3: Participants with TI NDMM will receive Bela-xRd and Belamaf-xRd. The combination treatment at Rd includes lenalidomide (R) and dexamethasone (d). x will be either a standard of care (SoC) or an emerging treatment. Description An open-lab multicentre, dose escalation and expansion trial to investigate the safety, tolerability and clinical activity of belantamab as monotherapy and in combination with other treatments in participants with multiple myeloma Timeline Trial start: Q3 2023 Data anticipates: 2026+ Key end points Part 1: Safety and tolerability, PK and recommended Part 2 dose Part 2: Safety and tolerability, PK and recommended Part 2 dose Chinactriate a Chinactriate a								amab	belant
Phase I/II Patient Relapsed/refractory multiple myeloma (RRMM) [Parts 1 and 2] Transplant-ineligible newly diagnosed multiple myeloma (TI NDMM) [Part 3] Subjects 124 Part 1: belantamab (may switch to belantamab mafodotin in case of PD) Part 2: Bela-xRd and Belamaf-xRd. The combination treatment xRd includes lenalidomide (R) and dexamethasone (d). x will be either a standard of care (SoC) or an emerging treatment. Part 3: Participants with TI NDMM will receive Bela-xRd and Belamaf-xRd. The combination treatment xRd includes lenalidomide (R) and dexamethasone (d). x will be either a standard of care (SoC) or an emerging treatment. Description An open-lab multicentre, dose escalation and expansion trial to investigate the safety, tolerability and clinical activity of belantamab as monotherapy and in combination with other treatments in participants with multiple myeloma Timeline Trial start: Q3 2023 Data anticipated: 2026+ Key end points Part 1: Safety and tolerability (including DLTs), PK and recommended Part 2 dose Part 3: Safety and tolerability, PK and efficacy Clinicatization PK and efficacy Clinicatization PK and efficacy									NOIMIN
Patient Relapsed/refractory multiple myeloma (RRMM) [Parts 1 and 2] Transplant-ineligible newly diagnosed multiple myeloma (TI NDMM) [Part 3] Subjects 124 Treatment arms Part 1: belantamab (may switch to belantamab mafodatin in case of PD) Part 2: Bela-xRd and Belamaf-xRd. The combination treatment xRd includes lenalidomide (R) and dexamethasone (d). x will be either a standard of care (SoC) or an emerging treatment. Part 3: Participants with TI NDMM will receive Bela-xRd and Belamaf-xRd. The combination treatment xRd includes lenalidomide (R) and dexamethasone (d). x will be either a standard of care (SoC) or an emerging treatment. Description An open-lab multicentre, dose escalation and expansion trial to investigate the safety, tolerability and clinical activity of belantamab as monotherapy and in combination with other treatments in participants with multiple myeloma Timeline Trial start: Q3 2023 Data anticipated: 2026+ Key end points Part 1: Safety and tolerability, PK and recommended Part 2 dose Part 2: Safety and tolerability, PK and recommended phase II dose Part 3: Safety and tolerability, PK and efficacy								- DREAMM-20	NCT05714839
Patient Transplant-ineligible newly diagnosed multiple myeloma (TI NDMM) [Part 3] Subjects 124 Part 1: belantamab (may switch to belantamab mafodotin in case of PD) Preatment arms Part 2: Bela-xRd and Belamaf-xRd. The combination treatment xRd includes lenalidomide (R) and dexamethasone (d). x will be either a standard of care (SoC) or an emerging treatment. Part 3: Participants with TI NDMM will receive Bela-xRd and Belamaf-xRd. The combination treatment xRd includes lenalidomide (R) and dexamethasone (d). x will be either a standard of care (SoC) or an emerging treatment Description An open-lab multicentre, dose escalation and expansion trial to investigate the safety, tolerability and clinical activity of belantamab as monotherapy and in combination with other treatments in participants with multiple myeloma Timeline Trial start: Q3 2023 Data anticipated: 2026+ Key end points Part 1: Safety and tolerability (including DLTs), PK and recommended Part 2 dose Part 2: Safety and tolerability, PK and recommended phase II dose Part 3: Safety and tolerability, PK and efficacy								1/11	Phase
Treatment Part 1: belantamab (may switch to belantamab mafodotin in case of PD) Part 2: Bela-xRd and Belamaf-xRd. The combination treatment xRd includes lenalidomide (R) and dexamethasone (d). x will be either a standard of care (SoC) or an emerging treatment. Part 3: Participants with TI NDMM will receive Bela-xRd and Belamaf-xRd. The combination treatment xRd includes lenalidomide (R) and dexamethasone (d). x will be either a standard of care (SoC) or an emerging treatment Description An open-lab multicentre, dose escalation and expansion trial to investigate the safety, tolerability and clinical activity of belantamab as monotherapy and in combination with other treatments in participants with multiple myeloma Timeline Trial start: Q3 2023 Data anticipated: 2026+ Part 1: Safety and tolerability (including DLTs), PK and recommended Part 2 dose Part 3: Safety and tolerability, PK and efficacy Clinicaltriate a							Patient		
Treatment arms Part 2: Bela-xRd and Belamaf-xRd. The combination treatment xRd includes lenalidomide (R) and dexamethasone (d). x will be either a standard of care (SoC) or an emerging treatment. Part 3: Participants with TI NDMM will receive Bela-xRd and Belamaf-xRd. The combination treatment xRd includes lenalidomide (R) and dexamethasone (d). x will be either a standard of care (SoC) or an emerging treatment Description An open-lab multicentre, dose escalation and expansion trial to investigate the safety, tolerability and clinical activity of belantamab as monotherapy and in combination with other treatments in participants with multiple myeloma Timeline Trial start: Q3 2023 Data anticipated: 2026+ Part 1: Safety and tolerability (including DLTs), PK and recommended Part 2 dose Part 2: Safety and tolerability, PK and efficacy Part 3: Safety and tolerability, PK and efficacy	124						Subjects		
Ireatment arms standard of care (SoC) or an emerging treatment. Part 3: Participants with TI NDMM will receive Bela-xRd and Belamaf-xRd. The combination treatment xRd includes lenalidomide (R) and dexamethasone (d). x will be either a standard of care (SoC) or an emerging treatment Description An open-lab multicentre, dose escalation and expansion trial to investigate the safety, tolerability and clinical activity of belantamab as monotherapy and in combination with other treatments in participants with multiple myeloma Timeline Trial start: Q3 2023 Data anticipated: 2026+ Key end points Part 1: Safety and tolerability (including DLTs), PK and recommended Part 2 dose Part 3: Safety and tolerability, PK and efficacy Cliniceltrials a			Part 1: belantamab (may switch to belantamab mafodotin in case of PD)						
dexamethasone (d). x will be either a standard of care (SoC) or an emerging treatment Description An open-lab multicentre, dose escalation and expansion trial to investigate the safety, tolerability and clinical activity of belantamab as monotherapy and in combination with other treatments in participants with multiple myeloma Timeline Trial start: Q3 2023 Data anticipated: 2026+ Key end points Part 1: Safety and tolerability (including DLTs), PK and recommended Part 2 dose Part 2: Safety and tolerability, PK and recommended phase II dose Part 3: Safety and tolerability, PK and efficacy									
Description monotherapy and in combination with other treatments in participants with multiple myeloma Timeline Trial start: Q3 2023 Data anticipated: 2026+ Key end points Part 1: Safety and tolerability (including DLTs), PK and recommended Part 2 dose Part 2: Safety and tolerability, PK and recommended phase II dose Part 3: Safety and tolerability, PK and efficacy Clinicaltrials a Clinical trials a									
Timeline Data anticipated: 2026+ Key end Part 1: Safety and tolerability (including DLTs), PK and recommended Part 2 dose Part 2: Safety and tolerability, PK and recommended phase II dose Part 3: Safety and tolerability, PK and efficacy						Description			
Data anticipated: 2026+ Key end points Part 1: Safety and tolerability (including DLTs), PK and recommended Part 2 dose Part 2: Safety and tolerability, PK and recommended phase II dose Part 3: Safety and tolerability, PK and efficacy							2023	Trial start: Q3 2	Timolino
Key end points Part 2: Safety and tolerability, PK and recommended phase II dose Part 3: Safety and tolerability, PK and efficacy							ed: 2026+	Data anticipat	
Part 2: Safety and tolerability, PK and recommended phase II dose Part 3: Safety and tolerability, PK and efficacy Clinicaltrials a					Part 2 dose	s), PK and recommended	nd tolerability (including D	Part 1: Safety a	
Part 3: Safety and tolerability, PK and efficacy Clinicaltrials a			Part 2: Safety and tolerability, PK and recommended phase II dose						
Clinicaltrials.g			Part 3: Safety and tolerability, PK and efficacy						
								<u>Link</u>	

Glossary

Oncology GSK4524101

NCT06077877

Phase	1/11		
Patient Adult participants with solid tumors			
Subjects 112			
	Arm A, Part 1: GSK4524101 monotherapy		
-	Arm B, Part 1: GSK4524101 plus niraparib		
Treatment arms	Arm C, Part 1: GSK4524101 food effect cohort		
anns	Arm D, Part 2: GSK4524101 plus niraparib		
	Arm E, Part 2: Niraparib		
Description	A first-time-in-human, open-label, multicentre, dose escalation and expansion study of the oral DNA Polymerase Theta inhibitor (POLQi) GSK4524101 and the PARP inhibitor (PARPi) <i>Niraparib</i> in adult participants with solid tumors		
T ime a I im a	Trial start: Q4 2023		
Timeline	Data anticipated: 2025		
Key end points	DLTs, AEs, SAEs, ORR		
Clinicaltrials.g ov	Link		

Opportunity driven

Glossary

Opportunity driven linerixibat

 NCT04950127 - GLISTEN

 Phase
 III

 Patient
 Participants with primary biliary cholangitis (PBC)

 Subjects
 230

 Treatment
 Arm A: linerixibat

 arms
 Arm B: linerixibat followed by placebo

 arms
 Arm C: placebo

 Arm D: placebo followed by linerixibat

 Description
 A two-part randomised, placebo controlled, double blind, multicentre trial to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic prurities in participants with primary biliary cholangitis

Description	evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants with primary biliary cholangitis
Timeline	Trial start: Q3 2021
Timeline	Data anticipated: H2 2024
V 1	Change from handling in monthly itch accurs over 24 weeks using Numerical
Key end points	Change from baseline in monthly itch scores over 24 weeks using Numerical Rating Scale (NRS)

Opportunity driven GSK4532990 (Non-alcoholic steathohepatitis)

NCT05583344 - HORIZON

Phase	llb			
Patient Adults with non-alcoholic steatohepatitis (NASH) and advanced fib				
Subjects 246				
Treatment arms	Arm 1: high dose GSK4532990 Arm 2: low dose GSK4532990 Arm 3: placebo			
Description	A placebo-controlled trial to evaluate the efficacy and safety of GSK4532990 in adults with pre-cirrhotic non-alcoholic steatohepatitis (NASH)			
Timeline	Trial start: Q1 2023 Data anticipated: 2025			
Key end	Part 1: Percentage of participants achieving ≥ 1 stage improvement in histological fibrosis with no worsening of NASH (at week 52)			
points	Part 2: Percentage of participants achieving NASH resolution with no worsening of fibrosis (at week 52)			
Clinicaltrials.g ov	Link			

Opportunity driven GSK4172239 (Sickle cell disease)

NCT05660265

Phase	I		
Patient	Participants with sickle cell disease		
Subjects 40			
	Cohort 1: GSK4172239D (Dose 1)		
	Cohort 2: GSK4172239D (Dose 2)		
Treatment	Cohort 3: GSK4172239D (Dose 3)		
arms	Cohort 4: GSK4172239D (Dose 4)		
	Cohort 5: GSK4172239D (Dose 5)		
	Food effect cohort		
Description	A randomised, placebo-controlled, double-blind (sponsor unblind), parallel group, single dose, dose escalation to evaluate the safety, tolerability and pharmacokinetics of GSK4172239D		
	Trial start: Q3 2023		
Timeline	Data anticipated: 2025		
Key end points	Area under curve zero to time infinity (AUC 0-inf) for GSK4106401 after a single oral dose of GSK4172239D		
Clinicaltrials.g ov			

Innovation: Pipeline growth	Infectious diseases	HIV	Respiratory/Immunology	Oncology	Opportunity driven	Glossary
Glossarv						

Glossary

Glossary

	ADC	Antibody drug conjugate
	AE	Adverse event
	AESI	Adverse event of special interest
	AUC	Area under curve
	BCMA	B-cell maturation antigen
	BICR	Blinded Independent Central Review
	BRCA	Breast cancer
	CAE	Corneal adverse events
	CBR	Clinical benefit rate
	cCR	Complete clinical response
	CKD	Chronic kidney disease
	CfB	Change from baseline
	CMV	Cytomegalovirus
	CN	China
	COPD	Chronic obstructive pulmonary disease
	СР	Cholestatic pruritus
	CRR	Complete response rate
	CRSwNP	Chronic rhinosinusitis with nasal polyps
	cUTI	Complicated urinary tract infection
	CV	Cardiovascular
	DDI	Drug-drug interaction
	DFS	Disease-freee survival
	DL	Dose level
	DLT	Dose-limiting toxicity
	dMMR	Deficient mismatch repair
	DoR	Duration of response
	DPNP	Diabetic peripheral neuropathic pain
	EASI	Eczema Area and Severity Index
	EGPA	Eosinophilic granulomatosis with polyangiitis
G	5K	

EGPA	Eosinophilic granulomatosis with polyangiitis
FVC	Forced vital capacity
GC	Urogenital gonorrhea
GMMA	Generalised Modules for Membrane Antigens
GSI	Gamma secretase inhibitor
HA	Healthy adults
HBV	Hepatitis B virus
HES	Hypereosinophilic syndrome
Hgb	Hemoglobin
hSBA	Human serum bactericidal assay
HZ	Herpes zoster
IC	Immunocompromised
ICR	Independent central review
iNTS	Invasive non-typhoidal salmonella
ITT	Intention-to-treat
JP	Japan
LLOQ	Lower limit of quantitation
LRTS	Lower respiratory tract symptoms
MAD	Multiple ascending dose
MAE	Medical attended events
MDI	Metered dose inhaler
MAPS	Mulitple Antigen Presenting System
MM	Multiple myeloma
MMR	Measles, mumps and rubella
MMRV	Measles, mumps, rubella and varicella
MRD	Multiple rising dose
MSI-H	Microsatellite instability high
NASH	Nonalcoholic steatohepatitis
NRS	Numeric Rating Scale

NSCLC	Non-small cell lung cancer
OMV	Outer membrane vesicle
ORR	Overall response rate
OS	Overall surival
PBC	Primary biliry cholangitis
PFS	Progression-free survival
PFS2	Time to second disease progression or death
РК	Pharmacokinetic
PMF	Primary myelofibrosis
Post-PV/ET MF	Post-essential thrombocythemia myelofibrosis
RCC	Refractory chronic cough
RL	Repeat dose level
RRMM	Relapsed/refractory multiple myeloma
RSV	Respiratory syncytial virus
SAD	Single ascending dose
SAE	Serious adverse event
siRNA	Small interfering RNA
SoC	Standard of care
SSc-ILD	Systemic sclerosis associated interstitial lung disease
тос	Test of cure
TTBR	Time to best response
TTD	Time to treatment discontinuation
ТТР	Time to tumour progression
TTR	Time to treatment response
UTI	Urinary tract infection
uUTI	Uncomplicated urinary tract infection
VGPR	Very good partial remission
VSP	Vital sign parameters
YoA	Years of age